Upregulation	O
of	O
c-Fos	B-protein
in	O
activated	B-cell_type
T	I-cell_type
lymphoid	I-cell_type
and	I-cell_type
monocytic	I-cell_type
cells	I-cell_type
by	O
human	B-protein
immunodeficiency	I-protein
virus-1	I-protein
Tat	I-protein
protein	I-protein
.	O

The	O
regulatory	B-protein
Tat	I-protein
protein	I-protein
of	O
the	O
human	O
immunodeficiency	O
virus	O
type-1	O
(	O
HIV-1	O
)	O
is	O
essential	O
for	O
viral	O
replication	O
and	O
also	O
shows	O
pleiotropic	O
activities	O
on	O
various	O
cell	O
functions	O
.	O

To	O
get	O
further	O
insights	O
into	O
the	O
molecular	O
mechanisms	O
underlying	O
the	O
biological	O
activity	O
of	O
Tat	B-protein
,	O
we	O
investigated	O
the	O
effect	O
of	O
endogenous	O
and	O
exogenous	O
Tat	B-protein
protein	I-protein
on	O
c-fos	O
gene	O
expression	O
in	O
T	B-cell_line
lymphoblastoid	I-cell_line
(	I-cell_line
Jurkat	I-cell_line
)	I-cell_line
and	I-cell_line
monocytic	I-cell_line
(	I-cell_line
U937	I-cell_line
)	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
as	O
well	O
as	O
in	O
primary	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMC	B-cell_type
)	O
.	O

Transient	O
cotransfection	O
of	O
tat	B-DNA
cDNA	I-DNA
in	O
sense	O
orientation	O
(	O
tat/S	B-DNA
)	O
,	O
together	O
with	O
a	O
plasmid	B-DNA
containing	O
the	O
c-fos	B-DNA
promoter	I-DNA
(	O
FC3	B-DNA
,	O
from-	O
711	B-DNA
to	I-DNA
+42	I-DNA
)	O
in	O
front	O
of	O
the	O
bacterial	B-DNA
chloramphenicol	I-DNA
acetyltransferase	I-DNA
(	I-DNA
CAT	I-DNA
)	I-DNA
gene	I-DNA
significantly	O
enhanced	O
CAT	B-protein
activity	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
activated	O
by	O
the	O
addition	O
of	O
15	O
%	O
fetal	O
calf	O
serum	O
(	O
FCS	O
)	O
or	O
5	O
micrograms/mL	O
phytohemagglutinin	B-protein
plus	O
10	O
(	O
-7	O
)	O
mol/L	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
and	O
U937	B-cell_line
cells	I-cell_line
activated	O
by	O
15	O
%	O
FCS	O
or	O
10	O
(	O
-7	O
)	O
mol/L	O
PMA	O
.	O

This	O
effect	O
was	O
specifically	O
due	O
to	O
Tat	B-protein
,	O
since	O
Jurkat	B-cell_line
and	O
U937	B-cell_line
cells	I-cell_line
cotransfected	O
either	O
with	O
tat	B-DNA
cDNA	I-DNA
in	O
antisense	O
orientation	O
(	O
tat/AS	B-DNA
)	O
,	O
tat	B-DNA
carrying	O
a	O
mutation	O
in	O
the	O
aminoacid	B-protein
cys22-gly22	I-protein
(	O
tat	B-DNA
22/S	I-DNA
)	O
or	O
with	O
the	O
backbone	B-DNA
vector	I-DNA
alone	I-DNA
(	O
pRPneo-SL3	B-DNA
)	O
did	O
not	O
show	O
any	O
significant	O
difference	O
in	O
c-fos	B-DNA
promoter	I-DNA
activity	O
as	O
compared	O
to	O
cells	O
transfected	O
with	O
FC3	B-DNA
plasmid	I-DNA
alone	O
.	O

By	O
using	O
deletion	O
mutants	O
of	O
the	O
c-fos	B-DNA
promoter	I-DNA
,	O
we	O
found	O
that	O
the	O
minimal	B-DNA
DNA	I-DNA
sequence	I-DNA
required	O
for	O
Tat	B-protein
activity	O
was	O
located	O
between	O
nucleotides	B-DNA
-404/-220	I-DNA
and	O
that	O
the	O
serum	B-DNA
responsive	I-DNA
element	I-DNA
(	O
SRE	B-DNA
,	O
-317/-288	B-DNA
)	O
,	O
present	O
within	O
this	O
region	O
,	O
was	O
still	O
responsive	O
to	O
Tat	B-protein
.	O

A	O
single	B-DNA
point	I-DNA
mutation	I-DNA
in	O
the	O
SRE	B-DNA
completely	O
abrogated	O
the	O
responsiveness	O
to	O
tat/S	B-DNA
.	O

Exogenous	O
recombinant	B-protein
Tat	I-protein
protein	I-protein
was	O
also	O
able	O
to	O
upregulate	O
c-fos	B-DNA
promoter	I-DNA
activity	O
in	O
serum-activated	O
Jurkat	O
and	O
U937	B-cell_line
cells	I-cell_line
,	O
as	O
well	O
as	O
endogenous	O
c-fos	B-RNA
mRNA	I-RNA
expression	O
and	O
c-Fos	B-protein
protein	O
synthesis	O
in	O
both	O
serum-activated	B-cell_line
cell	I-cell_line
lines	I-cell_line
and	O
primary	B-cell_type
PBMC	I-cell_type
.	O

c-Fos	B-protein
protein	O
was	O
shown	O
essential	O
for	O
an	O
optimal	O
transactivation	O
of	O
the	O
HIV-1	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
by	O
Tat	B-protein
:	O
incubation	O
of	O
Jurkat	B-cell_line
cells	I-cell_line
with	O
antisense	O
,	O
but	O
not	O
sense	O
,	O
c-fos	O
oligonucleotides	O
significantly	O
reduced	O
either	O
the	O
Tat	B-protein
-enhanced	O
expression	O
of	O
an	O
LTR-CAT	B-DNA
reporter	I-DNA
construct	I-DNA
or	O
the	O
levels	O
of	O
gag	B-protein
p24	I-protein
in	O
the	O
culture	O
supernatants	O
of	O
Jurkat	B-cell_line
cells	I-cell_line
and	O
PBMC	B-cell_type
acutely	O
infected	O
with	O
HIV-1	O
.	O

Our	O
data	O
suggest	O
that	O
the	O
c-fos	B-DNA
upregulation	O
mediated	O
by	O
Tat	B-protein
might	O
play	O
a	O
significant	O
role	O
in	O
the	O
control	O
of	O
viral	O
gene	O
transactivation	O
.	O

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

Upregulation	NULL
of	NULL
c-Fos	NULL
in	NULL
Activated	NULL
T	NULL
Lymphoid	NULL
and	NULL
Monocytic	NULL
Cells	NULL
by	NULL
Human	NULL
Immunodeficiency	NULL
Virus-1	NULL
Tat	NULL
Protein	NULL
By	NULL
Davide	NULL
Gibellini	NULL
,	NULL
Antonella	NULL
Caputo	NULL
,	NULL
Silvano	NULL
Capitani	NULL
,	NULL
Michele	NULL
La	NULL
Placa	NULL
,	NULL
and	NULL
Giorgio	NULL
Zauli	NULL
The	NULL
regulatory	NULL
Tat	NULL
protein	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type-1	NULL
(	NULL
HIV-1	NULL
)	NULL
is	NULL
essential	NULL
for	NULL
viral	NULL
replication	NULL
and	NULL
also	NULL
shows	NULL
pleiotropic	NULL
activities	NULL
on	NULL
various	NULL
cell	NULL
functions	NULL
.	NULL

To	NULL
get	NULL
further	NULL
insights	NULL
into	NULL
the	NULL
molecular	NULL
mechanisms	NULL
underlying	NULL
the	NULL
biological	NULL
activity	NULL
of	NULL
Tat	NULL
,	NULL
we	NULL
investigated	NULL
the	NULL
effect	NULL
of	NULL
endogenous	NULL
and	NULL
exogenous	NULL
Tat	NULL
protein	NULL
on	NULL
c-fos	NULL
gene	NULL
expression	NULL
in	NULL
T	NULL
lymphoblastoid	NULL
(	NULL
Jurkat	NULL
)	NULL
and	NULL
monocytic	NULL
(	NULL
U937	NULL
)	NULL
cell	NULL
lines	NULL
,	NULL
as	NULL
well	NULL
as	NULL
in	NULL
primary	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
(	NULL
PBMC	NULL
)	NULL
.	NULL

Transient	NULL
cotransfection	NULL
of	NULL
tat	NULL
cDNA	NULL
in	NULL
sense	NULL
orientation	NULL
(	NULL
tat/S	NULL
)	NULL
,	NULL
together	NULL
with	NULL
a	NULL
plasmid	NULL
containing	NULL
the	NULL
c-fos	NULL
promoter	NULL
(	NULL
FC3	NULL
,	NULL
from	NULL
-711	NULL
to	NULL
+42	NULL
)	NULL
in	NULL
front	NULL
of	NULL
the	NULL
bacterial	NULL
chloramphenicol	NULL
acetyltransferase	NULL
(	NULL
CAT	NULL
)	NULL
gene	NULL
significantly	NULL
enhanced	NULL
CAT	NULL
activity	NULL
in	NULL
Jurkat	NULL
cells	NULL
activated	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
15	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
(	NULL
FCS	NULL
)	NULL
or	NULL
5	NULL
mg/ml	NULL
phytohemagglutinin	NULL
plus	NULL
10~	NULL
'	NULL
mol/L	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
(	NULL
PMA	NULL
)	NULL
and	NULL
U937	NULL
cells	NULL
activated	NULL
by	NULL
15	NULL
%	NULL
FCS	NULL
or	NULL
10~	NULL
'	NULL
mol/L	NULL
PMA	NULL
.	NULL

This	NULL
effect	NULL
was	NULL
specifically	NULL
due	NULL
to	NULL
Tat	NULL
,	NULL
since	NULL
Jurkat	NULL
and	NULL
U937	NULL
cells	NULL
cotransfected	NULL
either	NULL
with	NULL
tat	NULL
cDNA	NULL
in	NULL
antisense	NULL
orientation	NULL
(	NULL
fat/AS	NULL
}	NULL
)	NULL
,	NULL
tat	NULL
carrying	NULL
a	NULL
mutation	NULL
in	NULL
the	NULL
aminoacid	NULL
cys	NULL
``	NULL
-	NULL
gly	NULL
``	NULL
(	NULL
fat	NULL
/S	NULL
)	NULL
or	NULL
with	NULL
the	NULL
backbone	NULL
vector	NULL
alone	NULL
(	NULL
pRPneo-SL3	NULL
)	NULL
did	NULL
not	NULL
show	NULL
any	NULL
significant	NULL
difference	NULL
in	NULL
c-fos	NULL
promoter	NULL
activity	NULL
as	NULL
compared	NULL
to	NULL
cells	NULL
transfected	NULL
with	NULL
HE	NULL
HUMAN	NULL
immunodeficiency	NULL
virus-type	NULL
1	NULL
(	NULL
HIV-1	NULL
)	NULL
86-101	NULL
amino	NULL
acid	NULL
Tat	NULL
protein	NULL
is	NULL
encoded	NULL
by	NULL
two	NULL
exons	NULL
and	NULL
comprises	NULL
five	NULL
distinct	NULL
domains	NULL
:	NULL
namely	NULL
the	NULL
N-terminal	NULL
,	NULL
cysteine-rich	NULL
,	NULL
core	NULL
,	NULL
basic	NULL
,	NULL
and	NULL
C-terminal	NULL
sequences	NULL
.	NULL
``	NULL

The	NULL
cysteine-rich	NULL
region	NULL
is	NULL
responsible	NULL
for	NULL
the	NULL
formation	NULL
of	NULL
intra-molecular	NULL
disulphide	NULL
bonds	NULL
,	NULL
``	NULL
whereas	NULL
the	NULL
basic	NULL
region	NULL
contains	NULL
nuclear	NULL
localization	NULL
signals®	NULL
and	NULL
the	NULL
binding	NULL
site	NULL
for	NULL
the	NULL
transactivation	NULL
response	NULL
element	NULL
(	NULL
TAR	NULL
)	NULL
.	NULL

*	NULL
The	NULL
transcriptional	NULL
activation	NULL
domain	NULL
of	NULL
Tat	NULL
(	NULL
amino	NULL
acids	NULL
1	NULL
through	NULL
48	NULL
)	NULL
includes	NULL
the	NULL
amino-terminal	NULL
region	NULL
,	NULL
the	NULL
conserved	NULL
cysteine-rich	NULL
and	NULL
core	NULL
domains	NULL
.	NULL
``	NULL

Tat	NULL
plays	NULL
a	NULL
pivotal	NULL
role	NULL
for	NULL
HIV-1	NULL
gene	NULL
expression	NULL
and	NULL
replication	NULL
,	NULL
``	NULL
by	NULL
interacting	NULL
with	NULL
the	NULL
TAR	NULL
sequence	NULL
,	NULL
located	NULL
at	NULL
the	NULL
5	NULL
'	NULL
end	NULL
of	NULL
all	NULL
viral	NULL
mRNAs	NULL
.	NULL

However	NULL
,	NULL
increasing	NULL
experimental	NULL
evidence	NULL
suggests	NULL
that	NULL
Tat	NULL
can	NULL
also	NULL
control	NULL
viral	NULL
replication	NULL
via	NULL
TAR-independent	NULL
mecha-nisms	NULL
.	NULL
``	NULL

Besides	NULL
its	NULL
transactivating	NULL
function	NULL
on	NULL
viral	NULL
gene	NULL
expression	NULL
,	NULL
Tat	NULL
affects	NULL
the	NULL
survival	NULL
,	NULL
growth	NULL
,	NULL
and	NULL
function	NULL
of	NULL
a	NULL
variety	NULL
of	NULL
infected	NULL
and	NULL
uninfected	NULL
cells	NULL
.	NULL

*	NULL
``	NULL
``	NULL
These	NULL
biological	NULL
effects	NULL
are	NULL
at	NULL
least	NULL
partially	NULL
mediated	NULL
by	NULL
the	NULL
upregulation	NULL
or	NULL
downregulation	NULL
of	NULL
genes	NULL
involved	NULL
in	NULL
the	NULL
control	NULL
of	NULL
cell	NULL
sur-vival/proliferation'*	NULL
``	NULL
*	NULL
``	NULL
or	NULL
coding	NULL
for	NULL
cytokines	NULL
.	NULL
``	NULL

Tat	NULL
can	NULL
be	NULL
actively	NULL
secreted	NULL
by	NULL
HIV-1	NULL
infected	NULL
and	NULL
fat	NULL
From	NULL
Institute	NULL
of	NULL
Microbiology	NULL
,	NULL
University	NULL
of	NULL
Bologna	NULL
,	NULL
Bologna	NULL
,	NULL
Italy	NULL
;	NULL
Institute	NULL
of	NULL
Microbiology	NULL
,	NULL
University	NULL
of	NULL
Ferrara	NULL
,	NULL
Ferrara	NULL
;	NULL
and	NULL
Institute	NULL
of	NULL
Human	NULL
Anatomy	NULL
,	NULL
University	NULL
of	NULL
Ferrara	NULL
,	NULL
Ferrara	NULL
,	NULL
Italy	NULL
.	NULL

Submitted	NULL
May	NULL
9	NULL
,	NULL
1996	NULL
;	NULL
accepted	NULL
October	NULL
10	NULL
,	NULL
1996	NULL
.	NULL

Address	NULL
reprint	NULL
requests	NULL
to	NULL
Giorgio	NULL
Zauli	NULL
,	NULL
MD	NULL
,	NULL
PhD	NULL
,	NULL
Institute	NULL
of	NULL
Human	NULL
Anatomy	NULL
,	NULL
University	NULL
of	NULL
Ferrara	NULL
,	NULL
44100	NULL
Ferrara	NULL
,	NULL
Italy	NULL
.	NULL

The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
page	NULL
charge	NULL
payment	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

©	NULL
1997	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
.	NULL

0006-4971/97/8905-0116	NULL
$	NULL
3.00/0	NULL
1654	NULL
FC3	NULL
plasmid	NULL
alone	NULL
.	NULL

By	NULL
using	NULL
deletion	NULL
mutants	NULL
of	NULL
the	NULL
c-fos	NULL
promoter	NULL
,	NULL
we	NULL
found	NULL
that	NULL
the	NULL
minimal	NULL
DNA	NULL
sequence	NULL
required	NULL
for	NULL
Tat	NULL
activity	NULL
was	NULL
located	NULL
between	NULL
nucleotides	NULL
-404/-220	NULL
and	NULL
that	NULL
the	NULL
serum	NULL
responsive	NULL
element	NULL
(	NULL
SRE	NULL
,	NULL
-317/-288	NULL
)	NULL
,	NULL
present	NULL
within	NULL
this	NULL
region	NULL
,	NULL
was	NULL
still	NULL
responsive	NULL
to	NULL
Tat	NULL
.	NULL

A	NULL
single	NULL
point	NULL
mutation	NULL
in	NULL
the	NULL
SRE	NULL
completely	NULL
abrogated	NULL
the	NULL
responsiveness	NULL
to	NULL
fat/S	NULL
.	NULL

Exogenous	NULL
recombinant	NULL
Tat	NULL
protein	NULL
was	NULL
also	NULL
able	NULL
to	NULL
upregulate	NULL
c-fos	NULL
promoter	NULL
activity	NULL
in	NULL
serum-activated	NULL
Jurkat	NULL
and	NULL
U937	NULL
cells	NULL
,	NULL
as	NULL
well	NULL
as	NULL
endogenous	NULL
c-fos	NULL
mRNA	NULL
expression	NULL
and	NULL
c-Fos	NULL
protein	NULL
synthesis	NULL
in	NULL
both	NULL
serum-activated	NULL
cell	NULL
lines	NULL
and	NULL
primary	NULL
PBMC	NULL
.	NULL

c-Fos	NULL
protein	NULL
was	NULL
shown	NULL
essential	NULL
for	NULL
an	NULL
optimal	NULL
transactivation	NULL
of	NULL
the	NULL
HIV-1	NULL
long	NULL
terminal	NULL
repeat	NULL
(	NULL
LTR	NULL
)	NULL
by	NULL
Tat	NULL
:	NULL
incubation	NULL
of	NULL
Jurkat	NULL
cells	NULL
with	NULL
antisense	NULL
,	NULL
but	NULL
not	NULL
sense	NULL
,	NULL
c-fos	NULL
oligonucleotides	NULL
significantly	NULL
reduced	NULL
either	NULL
the	NULL
Tat-enhanced	NULL
expression	NULL
of	NULL
an	NULL
LTR-CAT	NULL
reporter	NULL
construct	NULL
or	NULL
the	NULL
levels	NULL
of	NULL
gag	NULL
p24	NULL
in	NULL
the	NULL
culture	NULL
supernatants	NULL
of	NULL
Jurkat	NULL
cells	NULL
and	NULL
PBMC	NULL
acutely	NULL
infected	NULL
with	NULL
HIV-1	NULL
.	NULL

Our	NULL
data	NULL
suggest	NULL
that	NULL
the	NULL
c-fos	NULL
upregulation	NULL
mediated	NULL
by	NULL
Tat	NULL
might	NULL
play	NULL
a	NULL
significant	NULL
role	NULL
in	NULL
the	NULL
control	NULL
of	NULL
viral	NULL
gene	NULL
transactivation	NULL
.	NULL

©	NULL
1997	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
.	NULL

transfected	NULL
cells	NULL
,	NULL
``	NULL
``	NULL
and	NULL
can	NULL
easily	NULL
enter	NULL
different	NULL
cell	NULL
types	NULL
both	NULL
in	NULL
vitro	NULL
``	NULL
'	NULL
``	NULL
``	NULL
and	NULL
in	NULL
vivo	NULL
,	NULL
``	NULL
contributing	NULL
to	NULL
the	NULL
transcellular	NULL
transactivation	NULL
of	NULL
HIV-1	NULL
long	NULL
terminal	NULL
repeat	NULL
(	NULL
LTR	NULL
)	NULL
promoter	NULL
in	NULL
latently	NULL
infected	NULL
cells	NULL
.	NULL
``	NULL

Moreover	NULL
,	NULL
the	NULL
addition	NULL
of	NULL
an	NULL
anti-Tat	NULL
neutralizing	NULL
antibody	NULL
in	NULL
culture	NULL
blocks	NULL
an	NULL
autocrine/paracrine	NULL
loop	NULL
of	NULL
extracellular	NULL
Tat	NULL
in	NULL
fat-transfected	NULL
cell	NULL
lines	NULL
,	NULL
``	NULL
``	NULL
and	NULL
reduces	NULL
the	NULL
levels	NULL
of	NULL
gag	NULL
p24	NULL
in	NULL
the	NULL
culture	NULL
supernatant	NULL
of	NULL
HIV-1	NULL
infected	NULL
lymphoid	NULL
T-cell	NULL
lines	NULL
and	NULL
primary	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
(	NULL
PBMCs	NULL
)	NULL
.	NULL

``	NULL
**°	NULL
These	NULL
findings	NULL
add	NULL
further	NULL
complexity	NULL
to	NULL
the	NULL
mechanisms	NULL
of	NULL
action	NULL
of	NULL
Tat	NULL
protein	NULL
,	NULL
strongly	NULL
suggesting	NULL
that	NULL
extracellular	NULL
Tat	NULL
may	NULL
also	NULL
significantly	NULL
contribute	NULL
to	NULL
the	NULL
pathogenesis	NULL
of	NULL
HIV-1	NULL
disease	NULL
.	NULL

It	NULL
is	NULL
noteworthy	NULL
that	NULL
c-Fos-responsive	NULL
sequence	NULL
motifs	NULL
have	NULL
been	NULL
identified	NULL
in	NULL
HIV-1	NULL
LTR	NULL
,	NULL
``	NULL
as	NULL
well	NULL
as	NULL
in	NULL
many	NULL
promoters	NULL
of	NULL
genes	NULL
encoding	NULL
for	NULL
cytokines	NULL
transactivated	NULL
by	NULL
Tat	NULL
.	NULL
``	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
investigated	NULL
whether	NULL
Tat	NULL
is	NULL
able	NULL
to	NULL
modulate	NULL
c-Fos	NULL
protein	NULL
expression	NULL
as	NULL
a	NULL
part	NULL
of	NULL
its	NULL
mechanism	NULL
of	NULL
action	NULL
.	NULL

To	NULL
do	NULL
this	NULL
,	NULL
we	NULL
selected	NULL
as	NULL
model	NULL
systems	NULL
the	NULL
Jurkat	NULL
human	NULL
CD4*	NULL
T	NULL
and	NULL
the	NULL
U937	NULL
monocytic	NULL
cell	NULL
lines	NULL
,	NULL
which	NULL
are	NULL
representative	NULL
of	NULL
the	NULL
main	NULL
targets	NULL
of	NULL
HIV-1	NULL
infection	NULL
in	NULL
vivo	NULL
.	NULL
``	NULL

Induction	NULL
of	NULL
the	NULL
c-fos	NULL
gene	NULL
promoter	NULL
,	NULL
c-fos	NULL
mRNA	NULL
expression	NULL
and	NULL
c-Fos	NULL
protein	NULL
synthesis	NULL
were	NULL
evaluated	NULL
in	NULL
both	NULL
cell	NULL
lines	NULL
,	NULL
either	NULL
(	NULL
1	NULL
)	NULL
transiently	NULL
transfected	NULL
with	NULL
tat	NULL
cDNA	NULL
,	NULL
or	NULL
(	NULL
2	NULL
)	NULL
treated	NULL
with	NULL
recombinant	NULL
Tat	NULL
protein	NULL
,	NULL
whether	NULL
alone	NULL
or	NULL
in	NULL
combination	NULL
with	NULL
various	NULL
stimuli	NULL
known	NULL
to	NULL
activate	NULL
c-fos	NULL
expression	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
extracellular	NULL
Tat	NULL
on	NULL
endogenous	NULL
c-fos	NULL
gene	NULL
expression	NULL
was	NULL
also	NULL
evaluated	NULL
on	NULL
primary	NULL
PBMCs	NULL
.	NULL

Finally	NULL
,	NULL
to	NULL
evaluate	NULL
the	NULL
physiological	NULL
relevance	NULL
of	NULL
these	NULL
results	NULL
to	NULL
HIV-1	NULL
infection	NULL
,	NULL
we	NULL
performed	NULL
experiments	NULL
in	NULL
which	NULL
antisense	NULL
and	NULL
sense	NULL
c-fos	NULL
oligonucleotides	NULL
were	NULL
added	NULL
to	NULL
Jurkat	NULL
cells	NULL
either	NULL
transfected	NULL
with	NULL
fat	NULL
cDNA	NULL
plus	NULL
constructs	NULL
containing	NULL
the	NULL
LTR	NULL
region	NULL
of	NULL
HIV1	NULL
genome	NULL
fused	NULL
with	NULL
a	NULL
chloramphenicol	NULL
acetyltransferase	NULL
(	NULL
CAT	NULL
)	NULL
,	NULL
or	NULL
acutely	NULL
infected	NULL
with	NULL
the	NULL
IIIB	NULL
strain	NULL
of	NULL
HIV-1	NULL
.	NULL

Blood	NULL
,	NULL
Vol	NULL
89	NULL
,	NULL
No	NULL
5	NULL
(	NULL
March	NULL
1	NULL
)	NULL
,	NULL
1997	NULL
:	NULL
pp	NULL
1654-1664	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

UPREGULATION	NULL
OF	NULL
C-FOS	NULL
BY	NULL
TAT	NULL
MATERIALS	NULL
AND	NULL
METHODS	NULL
Cell	NULL
lines	NULL
and	NULL
PBMCs	NULL
.	NULL

_	NULL
Jurkat	NULL
CD4	NULL
lymphoblastoid	NULL
T	NULL
and	NULL
U937	NULL
monocytic	NULL
cell	NULL
lines	NULL
were	NULL
obtained	NULL
from	NULL
the	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
(	NULL
Rockville	NULL
,	NULL
MD	NULL
)	NULL
and	NULL
maintained	NULL
in	NULL
RPMI	NULL
1640	NULL
(	NULL
GIBCO	NULL
Laboratories	NULL
,	NULL
Grand	NULL
Island	NULL
,	NULL
NY	NULL
)	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
(	NULL
FCS	NULL
;	NULL
GIBCO	NULL
)	NULL
at	NULL
an	NULL
optimal	NULL
cell	NULL
density	NULL
of	NULL
0.3	NULL
to	NULL
1.5	NULL
x	NULL
10°	NULL
cells/mL	NULL
.	NULL

PBMCs	NULL
were	NULL
taken	NULL
from	NULL
11	NULL
normal	NULL
blood	NULL
donors	NULL
,	NULL
who	NULL
gave	NULL
their	NULL
informed	NULL
consent	NULL
to	NULL
this	NULL
research	NULL
according	NULL
to	NULL
the	NULL
Helsinki	NULL
declaration	NULL
of	NULL
1975	NULL
.	NULL

Briefly	NULL
,	NULL
heparinized	NULL
(	NULL
20	NULL
U/mL	NULL
)	NULL
blood	NULL
samples	NULL
were	NULL
diluted	NULL
1:3	NULL
with	NULL
RPMI	NULL
1640	NULL
,	NULL
layered	NULL
over	NULL
Ficoll	NULL
Histopaque	NULL
(	NULL
d	NULL
=	NULL
1.077	NULL
g/mL	NULL
,	NULL
Pharmacia	NULL
,	NULL
Uppsala	NULL
,	NULL
Sweden	NULL
)	NULL
and	NULL
centrifuged	NULL
at	NULL
1,500	NULL
rpm	NULL
for	NULL
30	NULL
minutes	NULL
.	NULL

Light-density	NULL
mononuclear	NULL
cells	NULL
were	NULL
collected	NULL
,	NULL
washed	NULL
twice	NULL
,	NULL
counted	NULL
,	NULL
and	NULL
treated	NULL
with	NULL
various	NULL
agonists	NULL
.	NULL

Plasmids	NULL
,	NULL
-	NULL
oligonucleotides	NULL
,	NULL
-	NULL
and	NULL
viral	NULL
proteins	NULL
.	NULL

Plasmids	NULL
pRPneo-C/SL3/tat/S	NULL
,	NULL
pRPneo-C/SL3/tat	NULL
**/8	NULL
,	NULL
pRPneo-C/SL3/tat/	NULL
AS	NULL
containing	NULL
the	NULL
HIV-1	NULL
faf	NULL
cDNA	NULL
,	NULL
respectively	NULL
in	NULL
sense	NULL
(	NULL
¢at/S	NULL
)	NULL
,	NULL
carrying	NULL
a	NULL
mutation	NULL
in	NULL
the	NULL
aminoacid	NULL
cys*	NULL
-	NULL
gly	NULL
``	NULL
``	NULL
(	NULL
¥at	NULL
*°/	NULL
$	NULL
)	NULL
or	NULL
in	NULL
antisense	NULL
(	NULL
fat/AS	NULL
)	NULL
orientation	NULL
under	NULL
the	NULL
control	NULL
of	NULL
the	NULL
LTR	NULL
region	NULL
of	NULL
the	NULL
SL3	NULL
murine	NULL
leukemia	NULL
virus	NULL
were	NULL
derived	NULL
from	NULL
the	NULL
backbone	NULL
plasmid	NULL
,	NULL
as	NULL
previously	NULL
described	NULL
.	NULL
``	NULL

Antisense	NULL
and	NULL
sense	NULL
c-fos	NULL
oligonucleotides	NULL
were	NULL
represented	NULL
by	NULL
18	NULL
residues	NULL
starting	NULL
from	NULL
and	NULL
including	NULL
the	NULL
start	NULL
codon	NULL
for	NULL
c-fos	NULL
:	NULL
gene	NULL
:	NULL
ATG	NULL
ATG	NULL
TTC	NULL
TCG	NULL
GGT	NULL
TTC	NULL
AA	NULL
(	NULL
sense	NULL
c-fos	NULL
,	NULL
FOS-OLIGO	NULL
)	NULL
;	NULL
TTG	NULL
AAG	NULL
CCC	NULL
GAG	NULL
AAC	NULL
ATC	NULL
AT	NULL
(	NULL
antisense	NULL
c-fos	NULL
,	NULL
SOF-OLIGO	NULL
)	NULL
.	NULL

The	NULL
c-fos/CAT	NULL
plasmid	NULL
constructs	NULL
(	NULL
FC2	NULL
,	NULL
FC3	NULL
,	NULL
FC4	NULL
,	NULL
FC8	NULL
)	NULL
containing	NULL
the	NULL
bacterial	NULL
CAT	NULL
gene	NULL
under	NULL
the	NULL
control	NULL
of	NULL
various	NULL
c-fos	NULL
promoter	NULL
sequences	NULL
from	NULL
position	NULL
-1450	NULL
(	NULL
FC2	NULL
)	NULL
,	NULL
-711	NULL
(	NULL
FC3	NULL
)	NULL
,	NULL
-404	NULL
(	NULL
FCA	NULL
)	NULL
,	NULL
-220	NULL
(	NULL
FCB	NULL
)	NULL
to	NULL
position	NULL
+42	NULL
were	NULL
described	NULL
by	NULL
Deschamps	NULL
et	NULL
al	NULL
.	NULL
``	NULL

''	NULL
The	NULL
wild-type	NULL
serum	NULL
responsive	NULL
element	NULL
(	NULL
SRE	NULL
)	NULL
/CAT	NULL
plasmid	NULL
contained	NULL
c-fos	NULL
promoter	NULL
sequences	NULL
from	NULL
-317	NULL
to	NULL
-288	NULL
base	NULL
pairs	NULL
(	NULL
bp	NULL
)	NULL
.	NULL

The	NULL
mutated	NULL
SRE/CAT	NULL
plasmid	NULL
contained	NULL
two	NULL
point	NULL
mutations	NULL
(	NULL
CC-GG	NULL
)	NULL
in	NULL
positions	NULL
-309/-308	NULL
.	NULL

All	NULL
the	NULL
c-fos/CAT	NULL
plasmids	NULL
were	NULL
a	NULL
generous	NULL
gift	NULL
of	NULL
Dr	NULL
Sassone-Corsi	NULL
(	NULL
IGBMC	NULL
,	NULL
Illkirch	NULL
,	NULL
France	NULL
)	NULL
.	NULL

The	NULL
B-actin/CAT	NULL
and	NULL
the	NULL
HIV-1	NULL
LTR	NULL
were	NULL
described	NULL
previously	NULL
.	NULL
``	NULL

Recombinant	NULL
Tat	NULL
and	NULL
p24	NULL
proteins	NULL
,	NULL
produced	NULL
in	NULL
Escherichia	NULL
coli	NULL
(	NULL
ABT	NULL
,	NULL
Cambridge	NULL
,	NULL
MA	NULL
)	NULL
,	NULL
were	NULL
found	NULL
free	NULL
of	NULL
endotoxin	NULL
by	NULL
a	NULL
Limulus	NULL
Amebocyte	NULL
Lysate	NULL
test	NULL
(	NULL
Whittakers	NULL
,	NULL
Walkersville	NULL
,	NULL
MA	NULL
)	NULL
.	NULL

Transfections	NULL
.	NULL

Transient	NULL
cotransfection	NULL
experiments	NULL
were	NULL
carried	NULL
out	NULL
using	NULL
the	NULL
DEAE-dextran	NULL
method	NULL
as	NULL
previously	NULL
described	NULL
by	NULL
Zauli	NULL
et	NULL
al	NULL
.	NULL
``	NULL

''	NULL
Briefly	NULL
,	NULL
10	NULL
x	NULL
10°	NULL
of	NULL
exponentially	NULL
growing	NULL
Jurkat	NULL
or	NULL
U937	NULL
cells	NULL
were	NULL
maintained	NULL
in	NULL
RPMI	NULL
1640	NULL
plus	NULL
1	NULL
%	NULL
FCS	NULL
for	NULL
24	NULL
hours	NULL
and	NULL
then	NULL
transfected	NULL
in	NULL
3	NULL
mL	NULL
volume	NULL
with	NULL
15	NULL
pg	NULL
of	NULL
each	NULL
plasmid	NULL
DNA	NULL
in	NULL
500	NULL
ug	NULL
DEAE-dextran	NULL
for	NULL
90	NULL
minutes	NULL
.	NULL

After	NULL
trans-fection	NULL
,	NULL
cells	NULL
were	NULL
seeded	NULL
again	NULL
in	NULL
10	NULL
mL	NULL
of	NULL
RPMI	NULL
1640	NULL
plus	NULL
1	NULL
%	NULL
FCS	NULL
for	NULL
12	NULL
hours	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
supplemented	NULL
with	NULL
15	NULL
%	NULL
FCS	NULL
or	NULL
5	NULL
ug/mL	NULL
phytohemagglutinin	NULL
(	NULL
PHA	NULL
;	NULL
Difco	NULL
,	NULL
Detroit	NULL
,	NULL
MI	NULL
)	NULL
plus	NULL
10~	NULL
'	NULL
mol/L	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
(	NULL
PMA	NULL
,	NULL
Sigma	NULL
Chemicals	NULL
,	NULL
St	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
,	NULL
while	NULL
U937	NULL
cells	NULL
were	NULL
supplemented	NULL
with	NULL
15	NULL
%	NULL
FCS	NULL
or	NULL
10~	NULL
'	NULL
mol/L	NULL
PMA	NULL
for	NULL
an	NULL
additional	NULL
24	NULL
hours	NULL
.	NULL

Cells	NULL
were	NULL
then	NULL
lysed	NULL
and	NULL
the	NULL
clarified	NULL
lysates	NULL
were	NULL
assayed	NULL
for	NULL
CAT	NULL
activity	NULL
using	NULL
volumes	NULL
of	NULL
extract	NULL
corresponding	NULL
to	NULL
equal	NULL
amounts	NULL
of	NULL
proteins	NULL
as	NULL
determined	NULL
by	NULL
the	NULL
Bio-Rad	NULL
protein	NULL
assay	NULL
system	NULL
(	NULL
Bio-Rad	NULL
Laboratories	NULL
,	NULL
Rich-mond	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

In	NULL
other	NULL
experiments	NULL
,	NULL
10	NULL
X	NULL
10°	NULL
Jurkat	NULL
cells	NULL
were	NULL
transiently	NULL
transfected	NULL
with	NULL
15	NULL
ug	NULL
of	NULL
fat/	NULL
'S	NULL
plus	NULL
5	NULL
ug	NULL
of	NULL
LTR-CAT	NULL
plasmids	NULL
plus	NULL
either	NULL
sense	NULL
c-fos	NULL
(	NULL
FOS-OLIGO	NULL
,	NULL
25	NULL
umol/L	NULL
final	NULL
concentration	NULL
)	NULL
or	NULL
antisense	NULL
c-fos	NULL
(	NULL
SOF-OLIGO	NULL
,	NULL
25	NULL
pmol/L	NULL
final	NULL
concentration	NULL
)	NULL
oligonucleotides	NULL
,	NULL
then	NULL
treated	NULL
as	NULL
described	NULL
above	NULL
.	NULL

To	NULL
assay	NULL
the	NULL
effect	NULL
of	NULL
extracellular	NULL
Tat	NULL
on	NULL
the	NULL
c-fos	NULL
promoter	NULL
activity	NULL
,	NULL
5	NULL
X	NULL
10°	NULL
Jurkat	NULL
or	NULL
U937	NULL
cells	NULL
were	NULL
transiently	NULL
transfected	NULL
with	NULL
the	NULL
FC3	NULL
vector	NULL
as	NULL
described	NULL
above	NULL
.	NULL

Twelve	NULL
hours	NULL
after	NULL
transfec-tion	NULL
,	NULL
1	NULL
ug	NULL
of	NULL
recombinant	NULL
Tat	NULL
or	NULL
recombinant	NULL
p24	NULL
plus	NULL
15	NULL
%	NULL
FCS	NULL
1655	NULL
was	NULL
added	NULL
to	NULL
5	NULL
mL	NULL
of	NULL
medium	NULL
,	NULL
and	NULL
incubation	NULL
was	NULL
allowed	NULL
to	NULL
proceed	NULL
for	NULL
an	NULL
additional	NULL
24	NULL
hours	NULL
.	NULL

In	NULL
blocking	NULL
experiments	NULL
,	NULL
before	NULL
its	NULL
addition	NULL
to	NULL
the	NULL
culture	NULL
medium	NULL
,	NULL
recombinant	NULL
Tat	NULL
was	NULL
preincubated	NULL
for	NULL
2	NULL
hours	NULL
at	NULL
37°C	NULL
with	NULL
20	NULL
pg/mL	NULL
.	NULL

of	NULL
an	NULL
anti-Tat	NULL
monoclonal	NULL
antibody	NULL
(	NULL
MoAb	NULL
,	NULL
ABT	NULL
)	NULL
,	NULL
which	NULL
recognizes	NULL
the	NULL
N-terminus	NULL
of	NULL
Tat	NULL
or	NULL
with	NULL
20	NULL
ug/mL	NULL
of	NULL
an	NULL
anti-p24	NULL
MoAb	NULL
(	NULL
ABT	NULL
)	NULL
.	NULL

RNA	NULL
analysis	NULL
.	NULL

-	NULL
To	NULL
study	NULL
the	NULL
effect	NULL
of	NULL
extracellular	NULL
Tat	NULL
on	NULL
endogenous	NULL
c-fos	NULL
mRNA	NULL
expression	NULL
,	NULL
30	NULL
X	NULL
10°	NULL
Jurkat	NULL
were	NULL
cultured	NULL
in	NULL
RPMI	NULL
plus	NULL
1	NULL
%	NULL
FCS	NULL
for	NULL
24	NULL
hours	NULL
and	NULL
then	NULL
supplemented	NULL
with	NULL
15	NULL
%	NULL
FCS	NULL
or	NULL
PMA	NULL
plus	NULL
or	NULL
minus	NULL
5	NULL
pg	NULL
of	NULL
recombinant	NULL
Tat	NULL
or	NULL
p24	NULL
in	NULL
5	NULL
mL	NULL
of	NULL
medium	NULL
for	NULL
30	NULL
minutes	NULL
.	NULL

Total	NULL
RNA	NULL
was	NULL
extracted	NULL
,	NULL
using	NULL
the	NULL
RNAzol	NULL
kit	NULL
(	NULL
Biotecx	NULL
,	NULL
Galveston	NULL
,	NULL
TX	NULL
)	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
.	NULL

5	NULL
ug	NULL
of	NULL
poly	NULL
(	NULL
A*®	NULL
)	NULL
RNA	NULL
were	NULL
then	NULL
purified	NULL
from	NULL
each	NULL
sample	NULL
by	NULL
using	NULL
the	NULL
poly	NULL
(	NULL
A*	NULL
)	NULL
RNA	NULL
purification	NULL
kit	NULL
(	NULL
Qiagen	NULL
,	NULL
Hilden	NULL
,	NULL
Germany	NULL
)	NULL
and	NULL
processed	NULL
for	NULL
Northern	NULL
blot	NULL
as	NULL
previously	NULL
described	NULL
.	NULL
``	NULL

c-fos	NULL
and	NULL
control	NULL
probes	NULL
were	NULL
represented	NULL
by	NULL
the	NULL
Xho	NULL
I/Nco	NULL
I	NULL
2,700	NULL
bp	NULL
c-fos	NULL
fragment	NULL
``	NULL
and	NULL
by	NULL
the	NULL
Xba	NULL
I	NULL
780	NULL
bp	NULL
fragment	NULL
of	NULL
glyceraldeyde-3-phosphate	NULL
dehydrogenase	NULL
gene	NULL
(	NULL
GAPDH	NULL
)	NULL
,	NULL
``	NULL
respectively	NULL
.	NULL

Both	NULL
probes	NULL
were	NULL
digoxigenin-labeled	NULL
using	NULL
a	NULL
random	NULL
primer	NULL
labeling	NULL
kit	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
,	NULL
Postfack	NULL
,	NULL
Germany	NULL
)	NULL
,	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
.	NULL

For	NULL
RNase	NULL
protection	NULL
analysis	NULL
,	NULL
30	NULL
ug	NULL
of	NULL
total	NULL
RNA	NULL
were	NULL
processed	NULL
using	NULL
a	NULL
RNase	NULL
protection	NULL
kit	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
)	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
.	NULL

A	NULL
340	NULL
nucleotide	NULL
complementary	NULL
digoxigenin-labeled	NULL
RNA	NULL
from	NULL
FC3	NULL
was	NULL
used	NULL
as	NULL
a	NULL
probe	NULL
for	NULL
c-fos	NULL
CAT	NULL
mRNA	NULL
.	NULL
``	NULL

Analysis	NULL
of	NULL
c-Fos	NULL
protein	NULL
by	NULL
flow	NULL
cytometry	NULL
and	NULL
confocal	NULL
microscopy	NULL
.	NULL

-	NULL
5	NULL
xX	NULL
10°	NULL
Jurkat	NULL
cells	NULL
or	NULL
PBMC	NULL
were	NULL
cultured	NULL
in	NULL
RPMI	NULL
plus	NULL
1	NULL
%	NULL
FCS	NULL
for	NULL
24	NULL
hours	NULL
and	NULL
then	NULL
supplemented	NULL
with	NULL
15	NULL
%	NULL
FCS	NULL
alone	NULL
or	NULL
in	NULL
combination	NULL
with	NULL
Tat	NULL
or	NULL
p24	NULL
for	NULL
45	NULL
minutes	NULL
.	NULL

Cells	NULL
were	NULL
then	NULL
fixed	NULL
and	NULL
permeabilized	NULL
with	NULL
cold	NULL
70	NULL
%	NULL
ethanol	NULL
for	NULL
30	NULL
minutes	NULL
at	NULL
4°C	NULL
,	NULL
washed	NULL
twice	NULL
with	NULL
phosphate-buffered	NULL
saline	NULL
(	NULL
PBS	NULL
)	NULL
,	NULL
and	NULL
treated	NULL
for	NULL
90	NULL
minutes	NULL
at	NULL
37°C	NULL
with	NULL
a	NULL
1:100	NULL
dilution	NULL
of	NULL
anti-c-Fos	NULL
rabbit	NULL
polyclonal	NULL
serum	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotech	NULL
,	NULL
Santa	NULL
Cruz	NULL
,	NULL
CA	NULL
)	NULL
in	NULL
PBS	NULL
plus	NULL
1	NULL
%	NULL
bovine	NULL
serum	NULL
albumin	NULL
(	NULL
BSA	NULL
)	NULL
.	NULL

2.5	NULL
%	NULL
of	NULL
nonspecific	NULL
blocking	NULL
guinea	NULL
pig	NULL
serum	NULL
was	NULL
present	NULL
during	NULL
each	NULL
antibody	NULL
incubation	NULL
.	NULL

Cells	NULL
were	NULL
washed	NULL
twice	NULL
and	NULL
incubated	NULL
for	NULL
30	NULL
minutes	NULL
at	NULL
37°C	NULL
with	NULL
a	NULL
1:100	NULL
dilution	NULL
of	NULL
goat	NULL
anti-rabbit	NULL
serum	NULL
conjugated	NULL
to	NULL
fluorescein	NULL
(	NULL
GAR-FITC	NULL
,	NULL
Sigma	NULL
)	NULL
in	NULL
PBS	NULL
plus	NULL
1	NULL
%	NULL
BSA	NULL
.	NULL

Negative	NULL
controls	NULL
consisted	NULL
of	NULL
normal	NULL
rabbit	NULL
serum	NULL
followed	NULL
by	NULL
identical	NULL
second	NULL
layer	NULL
labeling	NULL
as	NULL
above	NULL
.	NULL

The	NULL
presence	NULL
and	NULL
subcellular	NULL
distribution	NULL
of	NULL
c-Fos	NULL
protein	NULL
was	NULL
investigated	NULL
by	NULL
FACScan	NULL
using	NULL
the	NULL
Lysis	NULL
II	NULL
software	NULL
(	NULL
Becton	NULL
Dickinson	NULL
,	NULL
San	NULL
José	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

For	NULL
confocal	NULL
microscopy	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
first	NULL
spun	NULL
on	NULL
coverslips	NULL
,	NULL
then	NULL
fixed	NULL
and	NULL
stained	NULL
with	NULL
the	NULL
anti-Fos	NULL
antibody	NULL
as	NULL
described	NULL
above	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
analyzed	NULL
by	NULL
means	NULL
of	NULL
a	NULL
MCR-1000	NULL
confocal	NULL
microscopy	NULL
(	NULL
Bio-Rad	NULL
Microscience	NULL
Ltd	NULL
,	NULL
Hemel	NULL
,	NULL
Hempstead	NULL
,	NULL
UK	NULL
)	NULL
equipped	NULL
with	NULL
a	NULL
krypton/argon	NULL
ion	NULL
laser	NULL
emitting	NULL
at	NULL
488	NULL
nm	NULL
.	NULL

The	NULL
signal	NULL
was	NULL
achieved	NULL
through	NULL
an	NULL
Epide-tector	NULL
filter	NULL
(	NULL
passing	NULL
band	NULL
522/35	NULL
nm	NULL
)	NULL
,	NULL
analyzed	NULL
by	NULL
CoMOS	NULL
software	NULL
(	NULL
Bio-Rad	NULL
)	NULL
and	NULL
printed	NULL
on	NULL
a	NULL
Ektachrome	NULL
64T-Kodak	NULL
film	NULL
(	NULL
Eastman	NULL
Kodak	NULL
,	NULL
Rochester	NULL
,	NULL
NY	NULL
)	NULL
by	NULL
a	NULL
Focus	NULL
Imagecorder	NULL
Plus	NULL
(	NULL
Focus	NULL
Graph-ics	NULL
,	NULL
Inc	NULL
,	NULL
Foster	NULL
City	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Acute	NULL
HIV-1	NULL
infection	NULL
of	NULL
Jurkat	NULL
cells	NULL
and	NULL
primary	NULL
PBMC	NULL
.	NULL

-	NULL
Virus	NULL
stock	NULL
was	NULL
represented	NULL
by	NULL
the	NULL
supernatant	NULL
of	NULL
H9	NULL
lymphoblastoid	NULL
T	NULL
cells	NULL
cultured	NULL
at	NULL
optimal	NULL
cell	NULL
density	NULL
(	NULL
0.5	NULL
to	NULL
1.5	NULL
%	NULL
10°	NULL
cells/mL	NULL
)	NULL
and	NULL
obtained	NULL
14	NULL
days	NULL
after	NULL
infection	NULL
with	NULL
HIV-1	NULL
(	NULL
strain	NULL
IIIB	NULL
)	NULL
.	NULL

It	NULL
contained	NULL
a	NULL
reverse	NULL
transcriptase	NULL
activity	NULL
of	NULL
1.5	NULL
x	NULL
10°	NULL
cpm/mL	NULL
with	NULL
an	NULL
infectiv-ity	NULL
of	NULL
3	NULL
x	NULL
10°	NULL
TCID50	NULL
(	NULL
tissue	NULL
culture	NULL
infectious	NULL
dose	NULL
50	NULL
%	NULL
)	NULL
equivalents	NULL
for	NULL
lymphocytes	NULL
,	NULL
determined	NULL
as	NULL
previously	NULL
described	NULL
.	NULL
``	NULL

One	NULL
milliliter	NULL
of	NULL
HIV-1	NULL
was	NULL
added	NULL
to	NULL
either	NULL
Jurkat	NULL
cells	NULL
or	NULL
primary	NULL
PBMC	NULL
for	NULL
2	NULL
hours	NULL
at	NULL
37°C	NULL
.	NULL

Control	NULL
(	NULL
mock-treated	NULL
)	NULL
cultures	NULL
were	NULL
run	NULL
in	NULL
parallel	NULL
by	NULL
challenging	NULL
Jurkat	NULL
cells	NULL
or	NULL
PBMC	NULL
with	NULL
1	NULL
mL	NULL
of	NULL
the	NULL
supernatant	NULL
of	NULL
uninfected	NULL
H9	NULL
lymphoblastoid	NULL
T	NULL
cells	NULL
cultured	NULL
under	NULL
optimal	NULL
conditions	NULL
.	NULL

After	NULL
virus	NULL
absorption	NULL
,	NULL
Jurkat	NULL
and	NULL
PBMC	NULL
were	NULL
washed	NULL
and	NULL
adjusted	NULL
to	NULL
the	NULL
concentration	NULL
of	NULL
1	NULL
x	NULL
10°/mL	NULL
and	NULL
seeded	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

1656	NULL
in	NULL
1	NULL
mL	NULL
of	NULL
RPMI	NULL
containing	NULL
15	NULL
%	NULL
FCS	NULL
.	NULL

SOF-OLIGO	NULL
and	NULL
FOS-OLIGO	NULL
were	NULL
added	NULL
at	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
25	NULL
umol/L	NULL
at	NULL
the	NULL
beginning	NULL
of	NULL
culture	NULL
.	NULL

Every	NULL
other	NULL
day	NULL
,	NULL
cultures	NULL
were	NULL
demi-populated	NULL
and	NULL
supplemented	NULL
with	NULL
0.5	NULL
mL	NULL
of	NULL
fresh	NULL
medium	NULL
containing	NULL
25	NULL
pmol/	NULL
L	NULL
of	NULL
oligonucleotides	NULL
.	NULL

The	NULL
harvested	NULL
medium	NULL
was	NULL
centrifuged	NULL
and	NULL
the	NULL
supernatants	NULL
were	NULL
monitored	NULL
for	NULL
the	NULL
presence	NULL
of	NULL
gag	NULL
p24	NULL
antigen	NULL
by	NULL
means	NULL
of	NULL
a	NULL
commercial	NULL
immunoplate	NULL
assay	NULL
(	NULL
Du	NULL
Pont	NULL
de	NULL
Nemours	NULL
,	NULL
Les	NULL
Ulis	NULL
,	NULL
France	NULL
)	NULL
,	NULL
while	NULL
cell	NULL
pellet	NULL
was	NULL
resuspended	NULL
and	NULL
viable	NULL
cells	NULL
were	NULL
counted	NULL
by	NULL
Trypan	NULL
blue	NULL
dye	NULL
exclusion	NULL
.	NULL

Statistical	NULL
analysis	NULL
.	NULL

-	NULL
The	NULL
results	NULL
are	NULL
expressed	NULL
as	NULL
means	NULL
+	NULL
standard	NULL
deviations	NULL
(	NULL
SDs	NULL
)	NULL
of	NULL
at	NULL
least	NULL
three	NULL
separate	NULL
experiments	NULL
performed	NULL
in	NULL
duplicate	NULL
.	NULL

Two-tailed	NULL
Student	NULL
's	NULL
test	NULL
for	NULL
unpaired	NULL
data	NULL
was	NULL
used	NULL
for	NULL
statistical	NULL
comparison	NULL
.	NULL

RESULTS	NULL
HIV-1	NULL
Tat	NULL
specifically	NULL
upregulates	NULL
c-fos	NULL
promoter	NULL
activity	NULL
in	NULL
serum-stimulated	NULL
Jurkat	NULL
and	NULL
U937	NULL
cells	NULL
.	NULL

-	NULL
Since	NULL
Tat	NULL
protein	NULL
is	NULL
predominantly	NULL
produced	NULL
during	NULL
the	NULL
early	NULL
phases	NULL
of	NULL
de	NULL
novo	NULL
HIV-1	NULL
infection	NULL
or	NULL
during	NULL
reactivation	NULL
from	NULL
viral	NULL
latency	NULL
,	NULL
``	NULL
the	NULL
effect	NULL
of	NULL
Tat	NULL
on	NULL
the	NULL
c-fos	NULL
promoter	NULL
expression	NULL
was	NULL
first	NULL
examined	NULL
in	NULL
transient	NULL
transfection	NULL
experiments	NULL
.	NULL

Jurkat	NULL
and	NULL
U937	NULL
cell	NULL
lines	NULL
were	NULL
cotransfected	NULL
with	NULL
the	NULL
FC3	NULL
plasmid	NULL
,	NULL
where	NULL
CAT	NULL
gene	NULL
expression	NULL
is	NULL
driven	NULL
by	NULL
the	NULL
c-fos	NULL
promoter	NULL
,	NULL
together	NULL
with	NULL
an	NULL
HIV-1	NULL
fat	NULL
expression	NULL
plasmid	NULL
(	NULL
tat/S	NULL
)	NULL
.	NULL

Control	NULL
samples	NULL
were	NULL
represented	NULL
by	NULL
cells	NULL
transfected	NULL
with	NULL
the	NULL
FC3	NULL
plasmid	NULL
alone	NULL
as	NULL
well	NULL
as	NULL
cells	NULL
cotransfected	NULL
with	NULL
FC3	NULL
and	NULL
a	NULL
fat	NULL
antisense	NULL
plasmid	NULL
tat	NULL
carrying	NULL
a	NULL
mutation	NULL
in	NULL
the	NULL
amino	NULL
acid	NULL
cys*	NULL
``	NULL
-	NULL
gly	NULL
``	NULL
(	NULL
fat	NULL
/S	NULL
)	NULL
or	NULL
FC3	NULL
and	NULL
the	NULL
pRPneo-SL3	NULL
backbone	NULL
vector	NULL
.	NULL

When	NULL
Jurkat	NULL
or	NULL
U937	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
low	NULL
serum	NULL
concentrations	NULL
(	NULL
RPMI	NULL
+	NULL
1	NULL
%	NULL
FCS	NULL
)	NULL
,	NULL
Tat	NULL
was	NULL
unable	NULL
to	NULL
upregulate	NULL
CAT	NULL
activity	NULL
over	NULL
the	NULL
levels	NULL
observed	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
control	NULL
vectors	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
Tat	NULL
expression	NULL
was	NULL
then	NULL
evaluated	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
additional	NULL
stimuli	NULL
:	NULL
15	NULL
%	NULL
FCS	NULL
or	NULL
PHA	NULL
(	NULL
5	NULL
pg/mL	NULL
)	NULL
+	NULL
10~	NULL
'	NULL
mol/L	NULL
PMA	NULL
for	NULL
Jurkat	NULL
,	NULL
15	NULL
%	NULL
FCS	NULL
,	NULL
or	NULL
10~	NULL
'	NULL
mol/L	NULL
PMA	NULL
for	NULL
U937	NULL
cells	NULL
.	NULL

Under	NULL
these	NULL
conditions	NULL
,	NULL
CAT	NULL
activity	NULL
showed	NULL
a	NULL
fivefold	NULL
to	NULL
sevenfold	NULL
increase	NULL
(	NULL
P	NULL
<	NULL
.01	NULL
)	NULL
in	NULL
both	NULL
Jurkat	NULL
(	NULL
Fig	NULL
1A	NULL
)	NULL
and	NULL
U937	NULL
(	NULL
Fig	NULL
1B	NULL
)	NULL
cells	NULL
cotransfected	NULL
with	NULL
tat/S	NULL
as	NULL
compared	NULL
to	NULL
cells	NULL
cotransfected	NULL
with	NULL
faW/AS	NULL
,	NULL
tat	NULL
``	NULL
/S	NULL
,	NULL
pRPneo-SL3	NULL
or	NULL
cells	NULL
transfected	NULL
with	NULL
FC3	NULL
alone	NULL
.	NULL

The	NULL
enhancing	NULL
effect	NULL
of	NULL
tat/S	NULL
on	NULL
FC3	NULL
activity	NULL
was	NULL
promoter	NULL
specific	NULL
,	NULL
as	NULL
Tat	NULL
did	NULL
not	NULL
significantly	NULL
upregulate	NULL
CAT	NULL
expression	NULL
when	NULL
the	NULL
reporter	NULL
CAT	NULL
gene	NULL
was	NULL
under	NULL
the	NULL
transcriptional	NULL
control	NULL
of	NULL
the	NULL
B-actin	NULL
promoter	NULL
(	NULL
G-actin/CAT	NULL
)	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

To	NULL
provide	NULL
an	NULL
additional	NULL
proof	NULL
that	NULL
the	NULL
increased	NULL
c-fos	NULL
promoter	NULL
activity	NULL
was	NULL
specifically	NULL
mediated	NULL
by	NULL
Tat	NULL
,	NULL
transient	NULL
cotransfection	NULL
assays	NULL
were	NULL
performed	NULL
with	NULL
fat/S	NULL
,	NULL
tat/AS	NULL
,	NULL
and	NULL
FC3	NULL
vectors	NULL
in	NULL
both	NULL
Jurkat	NULL
and	NULL
U937	NULL
cell	NULL
lines	NULL
cultured	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
15	NULL
%	NULL
FCS	NULL
.	NULL

fat/AS	NULL
significantly	NULL
(	NULL
P	NULL
<	NULL
.01	NULL
)	NULL
reduced	NULL
the	NULL
activation	NULL
of	NULL
FC3	NULL
mediated	NULL
by	NULL
fat/S	NULL
in	NULL
both	NULL
Jurkat	NULL
(	NULL
Fig	NULL
2A	NULL
)	NULL
and	NULL
U937	NULL
(	NULL
Fig	NULL
2B	NULL
)	NULL
cells	NULL
from	NULL
fivefold-sev-enfold	NULL
to	NULL
twofold-threefold	NULL
.	NULL

Moreover	NULL
,	NULL
to	NULL
exclude	NULL
the	NULL
possibility	NULL
that	NULL
Tat	NULL
activates	NULL
the	NULL
transcription	NULL
of	NULL
the	NULL
CAT	NULL
gene	NULL
in	NULL
an	NULL
unusual	NULL
start	NULL
site	NULL
,	NULL
RNase	NULL
protection	NULL
analysis	NULL
was	NULL
performed	NULL
using	NULL
an	NULL
RNA	NULL
probe	NULL
complementary	NULL
to	NULL
the	NULL
CAT	NULL
gene	NULL
(	NULL
Fig	NULL
3	NULL
)	NULL
.	NULL

After	NULL
RNase	NULL
digestion	NULL
,	NULL
the	NULL
protected	NULL
fragment	NULL
resulted	NULL
of	NULL
310	NULL
nucleotides	NULL
as	NULL
expected	NULL
.	NULL

An	NULL
increased	NULL
level	NULL
of	NULL
correctly	NULL
initiated	NULL
RNA	NULL
was	NULL
observed	NULL
in	NULL
Jurkat	NULL
cells	NULL
co	NULL
GIBELLINI	NULL
ET	NULL
AL	NULL
A	NULL
Jurkat	NULL
P	NULL
RPneo-C/SL3	NULL
phine	NULL
15	NULL
%	NULL
FCs	NULL
&	NULL
PMA	NULL
+PHA	NULL
tat-22/8	NULL
P	NULL
tat/AS	NULL
tat/S	NULL
0	NULL
2	NULL
4	NULL
6	NULL
8	NULL
CAT	NULL
activation	NULL
(	NULL
folds	NULL
)	NULL
U937	NULL
pRPneo-C/SL3	NULL
15	NULL
%	NULL
FCS	NULL
@	NULL
rma	NULL
tat-22/5	NULL
as	NULL
tat/AS	NULL
CAT	NULL
activation	NULL
(	NULL
folds	NULL
)	NULL
Fig	NULL
1	NULL
.	NULL

Upregulation	NULL
of	NULL
the	NULL
c-fos	NULL
promoter	NULL
activity	NULL
by	NULL
Tat	NULL
in	NULL
(	NULL
A	NULL
)	NULL
Jurkat	NULL
cells	NULL
activated	NULL
by	NULL
15	NULL
%	NULL
FCS	NULL
or	NULL
10~	NULL
'	NULL
mol/L	NULL
PMA	NULL
plus	NULL
5	NULL
pg/mL	NULL
PHA	NULL
and	NULL
(	NULL
B	NULL
)	NULL
U937	NULL
cells	NULL
activated	NULL
by	NULL
15	NULL
%	NULL
FCS	NULL
or	NULL
10~	NULL
'	NULL
mol/L	NULL
PMA	NULL
24	NULL
hours	NULL
after	NULL
serum-starvation	NULL
(	NULL
1	NULL
%	NULL
FCS	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
transiently	NULL
cotransfected	NULL
with	NULL
FC3	NULL
plus	NULL
tat/S	NULL
or	NULL
tat/AS	NULL
or	NULL
pRPneo-SL3	NULL
control	NULL
vector	NULL
.	NULL

CAT	NULL
activity	NULL
is	NULL
expressed	NULL
as	NULL
folds	NULL
of	NULL
activation	NULL
with	NULL
respect	NULL
to	NULL
cell	NULL
lines	NULL
transfected	NULL
with	NULL
FC3	NULL
alone	NULL
.	NULL

Data	NULL
are	NULL
reported	NULL
as	NULL
means	NULL
+	NULL
SDs	NULL
of	NULL
four	NULL
independent	NULL
transfection	NULL
experiments	NULL
performed	NULL
in	NULL
duplicate	NULL
.	NULL

transfected	NULL
with	NULL
FC3	NULL
and	NULL
tat/S	NULL
as	NULL
compared	NULL
to	NULL
cells	NULL
cotransfected	NULL
with	NULL
FC3	NULL
and	NULL
fat/AS	NULL
.	NULL

The	NULL
-317/-288	NULL
serum	NULL
responsive	NULL
element	NULL
of	NULL
the	NULL
c-fos	NULL
promoter	NULL
is	NULL
required	NULL
for	NULL
Tat	NULL
transactivation	NULL
in	NULL
activated	NULL
Jurkat	NULL
cells	NULL
.	NULL

In	NULL
the	NULL
next	NULL
series	NULL
of	NULL
cotransfection	NULL
assays	NULL
we	NULL
used	NULL
different	NULL
5	NULL
'	NULL
deletion	NULL
mutants	NULL
of	NULL
the	NULL
c-fos	NULL
promoter	NULL
linked	NULL
to	NULL
the	NULL
CAT	NULL
gene	NULL
(	NULL
Fig	NULL
4A	NULL
and	NULL
B	NULL
)	NULL
together	NULL
with	NULL
tat	NULL
expressing	NULL
vectors	NULL
,	NULL
to	NULL
determine	NULL
which	NULL
sequences	NULL
of	NULL
the	NULL
c-fos	NULL
promoter	NULL
were	NULL
required	NULL
for	NULL
Tat	NULL
function	NULL
.	NULL

Figure	NULL
4C	NULL
shows	NULL
the	NULL
CAT	NULL
analysis	NULL
in	NULL
Jurkat	NULL
cells	NULL
cultured	NULL
in	NULL
15	NULL
%	NULL
FCS	NULL
after	NULL
cotransfection	NULL
with	NULL
various	NULL
c-fos	NULL
promoter/CAT	NULL
deletion	NULL
mutants	NULL
plus	NULL
1at/S	NULL
or	NULL
tat/AS	NULL
.	NULL

In	NULL
the	NULL
presence	NULL
of	NULL
FC2	NULL
,	NULL
FC3	NULL
,	NULL
and	NULL
FC4	NULL
plasmids	NULL
,	NULL
tat	NULL
was	NULL
able	NULL
to	NULL
significantly	NULL
enhance	NULL
CAT	NULL
activity	NULL
with	NULL
respect	NULL
to	NULL
fat/AS	NULL
,	NULL
whereas	NULL
tat/S	NULL
was	NULL
unable	NULL
to	NULL
activate	NULL
CAT	NULL
expression	NULL
from	NULL
the	NULL
FC8	NULL
mutant	NULL
over	NULL
the	NULL
level	NULL
achieved	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
fat/AS	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
majority	NULL
of	NULL
the	NULL
Tat-induced	NULL
activation	NULL
was	NULL
mediated	NULL
by	NULL
c	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

UPREGULATION	NULL
OF	NULL
C-FOS	NULL
BY	NULL
TAT	NULL
8	NULL
7	NULL
J	NULL
»	NULL
4	NULL
.	NULL

Jurkat	NULL
e-5	NULL
a~	NULL
34	NULL
a	NULL
CAT	NULL
activation	NULL
(	NULL
folds	NULL
)	NULL
l	NULL
0	NULL
7	NULL
tat/	NULL
S	NULL
tat/	NULL
AS	NULL
tat/S	NULL
+	NULL
tat/AS	NULL
TJ	NULL
U937	NULL
CAT	NULL
activation	NULL
(	NULL
folds	NULL
)	NULL
p	NULL
O	NULL
P	NULL
E	NULL
2	NULL
«	NULL
o	NULL
.	NULL

if	NULL
tat/	NULL
S	NULL
tat/	NULL
AS	NULL
tat/S	NULL
+	NULL
tat/AS	NULL
Fig	NULL
2	NULL
.	NULL

-	NULL
Selective	NULL
blocking	NULL
of	NULL
the	NULL
effect	NULL
of	NULL
Tat	NULL
on	NULL
the	NULL
c-fos	NULL
promoter	NULL
activity	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Jurkat	NULL
and	NULL
(	NULL
B	NULL
)	NULL
U937	NULL
cells	NULL
were	NULL
transiently	NULL
cotransfected	NULL
with	NULL
tat/S	NULL
,	NULL
tat/	NULL
AS	NULL
and	NULL
FC3	NULL
.	NULL

Controls	NULL
are	NULL
represented	NULL
by	NULL
cells	NULL
cotransfected	NULL
with	NULL
FC3	NULL
together	NULL
with	NULL
tat/S	NULL
or	NULL
tat/AS	NULL
.	NULL

CAT	NULL
activity	NULL
is	NULL
expressed	NULL
as	NULL
folds	NULL
of	NULL
activation	NULL
with	NULL
respect	NULL
to	NULL
cell	NULL
lines	NULL
transfected	NULL
with	NULL
FC3	NULL
alone	NULL
.	NULL

Data	NULL
are	NULL
reported	NULL
as	NULL
means	NULL
+	NULL
SDs	NULL
of	NULL
three	NULL
independent	NULL
transfection	NULL
experiments	NULL
performed	NULL
in	NULL
duplicate	NULL
.	NULL

fos	NULL
promoter	NULL
sequences	NULL
located	NULL
between	NULL
positions	NULL
-404	NULL
and	NULL
-220	NULL
bp	NULL
.	NULL

In	NULL
this	NULL
region	NULL
,	NULL
different	NULL
cis-acting	NULL
regulatory	NULL
elements	NULL
exist	NULL
(	NULL
Fig	NULL
4A	NULL
)	NULL
which	NULL
may	NULL
be	NULL
responsible	NULL
for	NULL
the	NULL
transactivation	NULL
activity	NULL
mediated	NULL
by	NULL
Tat	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
this	NULL
184	NULL
bp	NULL
region	NULL
contains	NULL
multiple	NULL
promoter	NULL
elements	NULL
including	NULL
the	NULL
dyad	NULL
symmetry	NULL
element	NULL
that	NULL
encompasses	NULL
the	NULL
SRE	NULL
,	NULL
an	NULL
AP-1	NULL
site	NULL
,	NULL
the	NULL
platelet-derived	NULL
growth	NULL
factor	NULL
responsive	NULL
sequence	NULL
,	NULL
a	NULL
CRE	NULL
element	NULL
and	NULL
an	NULL
E1A-inducible	NULL
region	NULL
.	NULL
``	NULL

''	NULL
Since	NULL
it	NULL
has	NULL
previously	NULL
been	NULL
shown	NULL
that	NULL
the	NULL
SRE	NULL
is	NULL
essential	NULL
for	NULL
the	NULL
transactivation	NULL
of	NULL
c-fos	NULL
mediated	NULL
by	NULL
transactivating	NULL
Tax	NULL
protein	NULL
of	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
1	NULL
(	NULL
HTLV-1	NULL
)	NULL
,	NULL
``	NULL
in	NULL
the	NULL
next	NULL
series	NULL
of	NULL
experiments	NULL
,	NULL
we	NULL
cotransfected	NULL
tat/S	NULL
and	NULL
tat/AS	NULL
with	NULL
plasmids	NULL
containing	NULL
the	NULL
wild-type	NULL
SRE	NULL
in	NULL
front	NULL
of	NULL
CAT	NULL
(	NULL
Fig	NULL
4B	NULL
and	NULL
C	NULL
)	NULL
.	NULL

Tat	NULL
significantly	NULL
activated	NULL
the	NULL
SRE/CAT	NULL
plasmid	NULL
(	NULL
a	NULL
threefold	NULL
increase	NULL
of	NULL
CAT	NULL
activity	NULL
with	NULL
respect	NULL
to	NULL
fat/AS	NULL
)	NULL
,	NULL
although	NULL
to	NULL
a	NULL
lesser	NULL
extent	NULL
than	NULL
FC3	NULL
(	NULL
a	NULL
fivefold	NULL
to	NULL
sevenfold	NULL
increase	NULL
)	NULL
.	NULL

On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
1a	NULL
#	NULL
/S	NULL
was	NULL
unable	NULL
to	NULL
stimulate	NULL
CAT	NULL
activity	NULL
when	NULL
an	NULL
SRE	NULL
mutated	NULL
was	NULL
used	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
that	NULL
a	NULL
functional	NULL
wild-type	NULL
SRE	NULL
1657	NULL
was	NULL
involved	NULL
in	NULL
the	NULL
Tat-mediated	NULL
transactivation	NULL
of	NULL
the	NULL
c-fos	NULL
promoter	NULL
.	NULL

Extracellular	NULL
recombinant	NULL
Tat	NULL
is	NULL
able	NULL
to	NULL
upregulate	NULL
c-fos	NULL
promoter	NULL
activity	NULL
and	NULL
induce	NULL
nuclear	NULL
c-Fos	NULL
accumulation	NULL
in	NULL
both	NULL
Jurkat	NULL
cells	NULL
and	NULL
primary	NULL
PBMC	NULL
.	NULL

It	NULL
has	NULL
been	NULL
well-documented	NULL
that	NULL
Tat	NULL
can	NULL
be	NULL
secreted	NULL
in	NULL
a	NULL
biologically	NULL
active	NULL
form	NULL
either	NULL
by	NULL
acutely	NULL
infected	NULL
cells	NULL
or	NULL
by	NULL
fat-transfected	NULL
cell	NULL
lines	NULL
,	NULL
and	NULL
be	NULL
taken	NULL
up	NULL
by	NULL
neighboring	NULL
uninfected	NULL
cells	NULL
,	NULL
thus	NULL
contributing	NULL
to	NULL
the	NULL
transactivation	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR	NULL
and	NULL
heterologous	NULL
cellular	NULL
gene	NULL
promoters	NULL
.	NULL

To	NULL
test	NULL
the	NULL
effect	NULL
of	NULL
extracellular	NULL
Tat	NULL
protein	NULL
on	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
c-fos	NULL
promoter	NULL
,	NULL
recombinant	NULL
Tat	NULL
or	NULL
p24	NULL
were	NULL
added	NULL
to	NULL
Jurkat	NULL
and	NULL
U937	NULL
cells	NULL
12-hours	NULL
posttransfection	NULL
with	NULL
FC3	NULL
,	NULL
and	NULL
cultures	NULL
were	NULL
allowed	NULL
to	NULL
procede	NULL
for	NULL
an	NULL
additional	NULL
24	NULL
hours	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
5	NULL
,	NULL
CAT	NULL
activity	NULL
was	NULL
significantly	NULL
(	NULL
P	NULL
<	NULL
.01	NULL
)	NULL
enhanced	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
recombinant	NULL
Tat	NULL
but	NULL
not	NULL
by	NULL
recombinant	NULL
p24	NULL
.	NULL

Moreover	NULL
,	NULL
Tat	NULL
activity	NULL
was	NULL
specifically	NULL
neutralized	NULL
by	NULL
an	NULL
anti-Tat	NULL
MoAb	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
also	NULL
in	NULL
its	NULL
extracellular	NULL
form	NULL
Tat	NULL
was	NULL
able	NULL
to	NULL
upregulate	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
c-fos	NULL
promoter	NULL
.	NULL

An	NULL
episomial	NULL
c-fos	NULL
promoter/CAT	NULL
fusion	NULL
construct	NULL
differs	NULL
from	NULL
the	NULL
endogenous	NULL
c-fos	NULL
gene	NULL
with	NULL
respect	NULL
to	NULL
the	NULL
conformation	NULL
and	NULL
sequences	NULL
of	NULL
the	NULL
flanking	NULL
DNA	NULL
.	NULL

Therefore	NULL
,	NULL
in	NULL
the	NULL
next	NULL
group	NULL
of	NULL
experiments	NULL
we	NULL
evaluated	NULL
the	NULL
effect	NULL
of	NULL
extracellular	NULL
Tat	NULL
on	NULL
endogenous	NULL
c-fos	NULL
gene	NULL
expression	NULL
in	NULL
Jurkat	NULL
cells	NULL
.	NULL

Northern	NULL
blot	NULL
analysis	NULL
showed	NULL
that	NULL
the	NULL
endogenous	NULL
c-fos	NULL
mRNA	NULL
expression	NULL
was	NULL
markedly	NULL
higher	NULL
in	NULL
Jurkat	NULL
treated	NULL
with	NULL
15	NULL
%	NULL
FCS	NULL
plus	NULL
recombinant	NULL
Tat	NULL
as	NULL
compared	NULL
to	NULL
cells	NULL
treated	NULL
with	NULL
15	NULL
%	NULL
FCS	NULL
alone	NULL
or	NULL
15	NULL
%	NULL
FCS	NULL
plus	NULL
recombinant	NULL
p24	NULL
(	NULL
Fig	NULL
6	NULL
)	NULL
.	NULL

The	NULL
enhancing	NULL
effect	NULL
mediated	NULL
by	NULL
Tat	NULL
on	NULL
c-fos	NULL
mRNA	NULL
was	NULL
specifically	NULL
blocked	NULL
by	NULL
an	NULL
anti-Tat	NULL
neutralizing	NULL
antibody	NULL
.	NULL

In	NULL
parallel	NULL
experiments	NULL
,	NULL
the	NULL
amount	NULL
of	NULL
c-Fos	NULL
protein	NULL
was	NULL
then	NULL
evaluated	NULL
by	NULL
flow	NULL
cytometry	NULL
(	NULL
Fig	NULL
7A	NULL
through	NULL
N	NULL
)	NULL
in	NULL
both	NULL
serum-starved	NULL
Jurkat	NULL
and	NULL
freshly	NULL
isolated	NULL
PBMC	NULL
treated	NULL
with	NULL
the	NULL
same	NULL
agonists	NULL
described	NULL
above	NULL
for	NULL
the	NULL
c-fos	NULL
mRNA	NULL
studies	NULL
.	NULL

PBMC	NULL
were	NULL
examined	NULL
taking	NULL
into	NULL
account	NULL
that	NULL
primary	NULL
T	NULL
cells	NULL
and	NULL
monocytes	NULL
differ	NULL
from	NULL
tumor	NULL
cell	NULL
lines	NULL
in	NULL
growth	NULL
control	NULL
and	NULL
requirement	NULL
for	NULL
growth	NULL
factors	NULL
.	NULL

The	NULL
flow	NULL
cytometry	NULL
approach	NULL
was	NULL
chosen	NULL
,	NULL
since	NULL
it	NULL
has	NULL
been	NULL
previously	NULL
e	NULL
Fig	NULL
3	NULL
.	NULL

-	NULL
RNase	NULL
protection	NULL
analysis	NULL
of	NULL
c-fos	NULL
promoter/CAT	NULL
transcription	NULL
mediated	NULL
by	NULL
Tat	NULL
in	NULL
U937	NULL
cells	NULL
cotransfected	NULL
with	NULL
FC3	NULL
and	NULL
tat/	NULL
AS	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
or	NULL
tat/S	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

The	NULL
protected	NULL
fragment	NULL
was	NULL
310	NULL
nucleotides	NULL
long	NULL
as	NULL
expected	NULL
.	NULL

One	NULL
of	NULL
three	NULL
separate	NULL
experiments	NULL
is	NULL
shown	NULL
.	NULL

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

1658	NULL
A	NULL
GIBELLINI	NULL
ET	NULL
AL	NULL
+1200	NULL
-	NULL
+400	NULL
-300	NULL
-200	NULL
1	NULL
§	NULL
\\	NULL
Q	NULL
E-§	NULL
__	NULL
$	NULL
=	NULL
6	NULL
ERE	NULL
SIF	NULL
SRE	NULL
AP-1	NULL
NF-1	NULL
RCE	NULL
CRE	NULL
TATA	NULL
-1450	NULL
+42	NULL
F2	NULL
t	NULL
p	NULL
/	NULL
--	NULL
1-	NULL
{	NULL
Lcat	NULL
]	NULL
711°	NULL
+42	NULL
F3	NULL
~-	NULL
+-	NULL
[	NULL
CAT	NULL
=	NULL
+42	NULL
F4X	NULL
404	NULL
.	NULL

CAT	NULL
~220	NULL
+42	NULL
F8	NULL
x	NULL
--	NULL
--	NULL
--	NULL
--	NULL
CAT	NULL
-317	NULL
-288	NULL
wt	NULL
SRE	NULL
CAT	NULL
-317	NULL
-	NULL
-288	NULL
A	NULL
SRE	NULL
CAT	NULL
a	NULL
hol	NULL
€	NULL
g	NULL
3	NULL
Ks	NULL
Z	NULL
G6	NULL
Fig	NULL
4	NULL
.	NULL

Identification	NULL
of	NULL
the	NULL
c-fos	NULL
promoter	NULL
region	NULL
required	NULL
for	NULL
Tat	NULL
l	NULL
transactivation	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Schematic	NULL
map	NULL
of	NULL
the	NULL
c-fos	NULL
promoter	NULL
structure	NULL
.	NULL

(	NULL
B	NULL
)	NULL
2	NULL
The	NULL
5	NULL
endpoints	NULL
of	NULL
the	NULL
deletion	NULL
mutants	NULL
are	NULL
indicated	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Jurkat	NULL
cells	NULL
U	NULL
were	NULL
cotransfected	NULL
with	NULL
the	NULL
indicated	NULL
c-fos	NULL
promoter/CAT	NULL
constructs	NULL
plus	NULL
tat/S	NULL
or	NULL
tat/AS	NULL
.	NULL

CAT	NULL
activity	NULL
is	NULL
expressed	NULL
as	NULL
folds	NULL
of	NULL
activation	NULL
with	NULL
respect	NULL
to	NULL
cell	NULL
lines	NULL
transfected	NULL
with	NULL
FC3	NULL
alone	NULL
.	NULL

Data	NULL
are	NULL
reported	NULL
FCS	NULL
FC2	NULL
FC3	NULL
FC4	NULL
SRE	NULL
demonstrated	NULL
that	NULL
it	NULL
represents	NULL
the	NULL
most	NULL
sensitive	NULL
and	NULL
reliable	NULL
method	NULL
for	NULL
the	NULL
detection	NULL
of	NULL
nuclear	NULL
oncoproteins	NULL
,	NULL
including	NULL
c-Fos	NULL
,	NULL
in	NULL
hematopoietic	NULL
cells	NULL
.	NULL
``	NULL

''	NULL
c-Fos	NULL
protein	NULL
was	NULL
first	NULL
examined	NULL
in	NULL
24-hour	NULL
serum-starved	NULL
Jurkat	NULL
cells	NULL
(	NULL
Fig	NULL
7A	NULL
and	NULL
D	NULL
)	NULL
and	NULL
freshly	NULL
isolated	NULL
PBMC	NULL
(	NULL
Fig	NULL
7G	NULL
and	NULL
L	NULL
)	NULL
.	NULL

The	NULL
level	NULL
of	NULL
c-Fos	NULL
protein	NULL
significantly	NULL
increased	NULL
in	NULL
both	NULL
Jurkat	NULL
and	NULL
PBMC	NULL
(	NULL
Fig	NULL
7B	NULL
and	NULL
H	NULL
)	NULL
after	NULL
a	NULL
45-minute	NULL
treatment	NULL
with	NULL
15	NULL
%	NULL
FCS	NULL
or	NULL
PHA	NULL
plus	NULL
PMA	NULL
(	NULL
Fig	NULL
7E	NULL
and	NULL
M	NULL
)	NULL
and	NULL
showed	NULL
a	NULL
further	NULL
increase	NULL
when	NULL
recombinant	NULL
Tat	NULL
was	NULL
added	NULL
to	NULL
15	NULL
%	NULL
FCS	NULL
or	NULL
PHA	NULL
plus	NULL
PMA	NULL
(	NULL
Fig	NULL
7C	NULL
,	NULL
F	NULL
,	NULL
I	NULL
,	NULL
and	NULL
N	NULL
)	NULL
.	NULL

The	NULL
presence	NULL
of	NULL
c-Fos	NULL
protein	NULL
was	NULL
also	NULL
analyzed	NULL
in	NULL
Jurkat	NULL
cells	NULL
by	NULL
indirect	NULL
immunofluorescence	NULL
and	NULL
confocal	NULL
microscopy	NULL
(	NULL
Fig	NULL
8A	NULL
,	NULL
B	NULL
,	NULL
and	NULL
C	NULL
)	NULL
.	NULL

While	NULL
Jurkat	NULL
showed	NULL
weak	NULL
or	NULL
absent	NULL
staining	NULL
after	NULL
24	NULL
hours	NULL
of	NULL
serum	NULL
starvation	NULL
(	NULL
Fig	NULL
8A	NULL
)	NULL
,	NULL
the	NULL
addition	NULL
of	NULL
15	NULL
%	NULL
FCS	NULL
for	NULL
45	NULL
minutes	NULL
induced	NULL
an	NULL
intense	NULL
as	NULL
means	NULL
+	NULL
SDs	NULL
of	NULL
four	NULL
independent	NULL
transfection	NULL
experiments	NULL
performed	NULL
in	NULL
duplicate	NULL
.	NULL

green-yellow	NULL
positive	NULL
staining	NULL
(	NULL
Fig	NULL
8B	NULL
)	NULL
,	NULL
which	NULL
further	NULL
increased	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
Tat	NULL
(	NULL
Fig	NULL
8C	NULL
)	NULL
.	NULL

Addition	NULL
of	NULL
antisense	NULL
c-fos	NULL
oligonucleotides	NULL
in	NULL
culture	NULL
diminishes	NULL
the	NULL
Tat-mediated	NULL
transactivation	NULL
activity	NULL
on	NULL
HIV1	NULL
LTR	NULL
and	NULL
the	NULL
gag	NULL
p24	NULL
levels	NULL
in	NULL
the	NULL
culture	NULL
supernatants	NULL
of	NULL
acutely	NULL
IIIB	NULL
infected	NULL
Jurkat	NULL
cells	NULL
and	NULL
PBMC	NULL
.	NULL

|	NULL
The	NULL
experiments	NULL
described	NULL
thus	NULL
far	NULL
suggested	NULL
that	NULL
Tat	NULL
protein	NULL
was	NULL
able	NULL
to	NULL
upregulate	NULL
c-Fos	NULL
nuclear	NULL
protein	NULL
in	NULL
both	NULL
T	NULL
lymphoid	NULL
and	NULL
monocytic	NULL
cells	NULL
.	NULL

If	NULL
this	NULL
elevation	NULL
in	NULL
c-Fos	NULL
protein	NULL
is	NULL
relevant	NULL
to	NULL
the	NULL
ability	NULL
of	NULL
Tat	NULL
to	NULL
transactivate	NULL
HIV-1	NULL
LTR	NULL
,	NULL
preventing	NULL
this	NULL
increase	NULL
in	NULL
c-fos	NULL
expression	NULL
should	NULL
diminish	NULL
the	NULL
expression	NULL
of	NULL
HIV-1	NULL
LTR	NULL
and	NULL
be	NULL
detrimental	NULL
for	NULL
a	NULL
productive	NULL
viral	NULL
infection	NULL
.	NULL

Such	NULL
an	NULL
approach	NULL
has	NULL
been	NULL
used	NULL
successfully	NULL
to	NULL
analyze	NULL
the	NULL
role	NULL
of	NULL
c-Fos	NULL
in	NULL
regulating	NULL
the	NULL
expression	NULL
of	NULL
stromelysin	NULL
by	NULL
epidermal	NULL
growth	NULL
factor	NULL
,	NULL
``	NULL
``	NULL
and	NULL
of	NULL
collagenase	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

UPREGULATION	NULL
OF	NULL
C-FOS	NULL
BY	NULL
TAT	NULL
5.-Jurkat	NULL
3	NULL
0	NULL
4	NULL
€	NULL
£00	NULL
3	NULL
{	NULL
3	NULL
2	NULL
3	NULL
27	NULL
E	NULL
s	NULL
1—	NULL
O	NULL
Tat	NULL
Tat	NULL
+	NULL
anti-Tat	NULL
p24	NULL
Tat	NULL
+	NULL
anti-p24	NULL
Fig	NULL
5	NULL
.	NULL

-	NULL
Upregulation	NULL
of	NULL
the	NULL
c-fos	NULL
promoter	NULL
activity	NULL
by	NULL
extracellular	NULL
Tat	NULL
.	NULL

Twenty-four	NULL
hour	NULL
serum-starved	NULL
(	NULL
1	NULL
%	NULL
FCS	NULL
)	NULL
Jurkat	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
FC3	NULL
then	NULL
cultured	NULL
with	NULL
recombinant	NULL
Tat	NULL
or	NULL
recombinant	NULL
p24	NULL
.	NULL

Alternatively	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
recombinant	NULL
Tat	NULL
pretreated	NULL
with	NULL
a	NULL
MoAb	NULL
to	NULL
Tat	NULL
or	NULL
p24	NULL
.	NULL

CAT	NULL
activity	NULL
is	NULL
expressed	NULL
as	NULL
folds	NULL
of	NULL
activation	NULL
with	NULL
respect	NULL
to	NULL
cell	NULL
lines	NULL
transfected	NULL
with	NULL
FC3	NULL
alone	NULL
.	NULL

Data	NULL
are	NULL
reported	NULL
as	NULL
means	NULL
+	NULL
SDs	NULL
of	NULL
three	NULL
independent	NULL
transfection	NULL
experiments	NULL
performed	NULL
in	NULL
duplicate	NULL
.	NULL

by	NULL
integrin-derived	NULL
signals	NULL
.	NULL

*	NULL
``	NULL
Accordingly	NULL
,	NULL
we	NULL
used	NULL
synthetic	NULL
DNA	NULL
oligonucleotides	NULL
that	NULL
were	NULL
complementary	NULL
to	NULL
c-fos	NULL
mRNA	NULL
sequences	NULL
(	NULL
antisense	NULL
c-fos	NULL
oligonucleotides	NULL
,	NULL
SOF-OLIGO	NULL
)	NULL
or	NULL
identical	NULL
to	NULL
c-fos	NULL
mRNA	NULL
sequences	NULL
(	NULL
sense	NULL
c-fos	NULL
oligonucleotides	NULL
,	NULL
FOS-OLIGO	NULL
)	NULL
,	NULL
introducing	NULL
them	NULL
by	NULL
along	NULL
with	NULL
1at/S	NULL
and	NULL
an	NULL
LTR-CAT	NULL
construct	NULL
.	NULL

When	NULL
cultures	NULL
were	NULL
kept	NULL
in	NULL
15	NULL
%	NULL
FCS	NULL
for	NULL
the	NULL
last	NULL
24	NULL
hours	NULL
,	NULL
transfection	NULL
of	NULL
Jurkat	NULL
with	NULL
SOF-OLIGO	NULL
but	NULL
not	NULL
with	NULL
FOS-OLIGO	NULL
markedly	NULL
decreased	NULL
the	NULL
expression	NULL
of	NULL
HIV-1	NULL
LTR	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
(	NULL
Fig	NULL
9	NULL
)	NULL
.	NULL

On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
no	NULL
significant	NULL
differences	NULL
in	NULL
the	NULL
levels	NULL
of	NULL
LTR-CAT	NULL
activity	NULL
were	NULL
observed	NULL
when	NULL
cultures	NULL
were	NULL
kept	NULL
for	NULL
36	NULL
hours	NULL
in	NULL
1	NULL
%	NULL
FCS	NULL
after	NULL
transfection	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
results	NULL
suggested	NULL
that	NULL
c-Fos	NULL
protein	NULL
is	NULL
involved	NULL
in	NULL
the	NULL
Tat-mediated	NULL
regulation	NULL
of	NULL
HIV-1	NULL
LTR	NULL
.	NULL

On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
activation	NULL
of	NULL
LTR-CAT	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
fat	NULL
expression	NULL
was	NULL
very	NULL
low	NULL
and	NULL
did	NULL
not	NULL
allow	NULL
to	NULL
establish	NULL
whether	NULL
c-Fos	NULL
was	NULL
also	NULL
involved	NULL
in	NULL
the	NULL
basal	NULL
HIV-1	NULL
LTR-CAT	NULL
transcription	NULL
.	NULL

We	NULL
then	NULL
analyzed	NULL
the	NULL
levels	NULL
of	NULL
gag	NULL
p24	NULL
antigen	NULL
in	NULL
the	NULL
culture	NULL
supernatants	NULL
of	NULL
Jurkat	NULL
(	NULL
Fig	NULL
10A	NULL
)	NULL
or	NULL
PBMC	NULL
(	NULL
Fig	NULL
10B	NULL
)	NULL
acutely	NULL
infected	NULL
with	NULL
high	NULL
doses	NULL
of	NULL
infectious	NULL
HIV	NULL
(	NULL
IIIB	NULL
)	NULL
and	NULL
continously	NULL
supplemented	NULL
with	NULL
SOF-	NULL
and	NULL
FOS-OLIGO	NULL
.	NULL

The	NULL
addition	NULL
of	NULL
SOF-OLIGO	NULL
but	NULL
not	NULL
FOS-OLIGO	NULL
to	NULL
cultures	NULL
caused	NULL
a	NULL
specific	NULL
decrease	NULL
of	NULL
the	NULL
gag	NULL
24	NULL
levels	NULL
evaluated	NULL
over	NULL
a	NULL
15-day	NULL
culture	NULL
period	NULL
in	NULL
either	NULL
Jurkat	NULL
cells	NULL
or	NULL
PBMC	NULL
.	NULL

This	NULL
effect	NULL
was	NULL
not	NULL
due	NULL
to	NULL
a	NULL
toxic	NULL
effect	NULL
of	NULL
SOF-OLIGO	NULL
,	NULL
since	NULL
the	NULL
number	NULL
of	NULL
viable	NULL
cells	NULL
did	NULL
not	NULL
significantly	NULL
change	NULL
in	NULL
Jurkat	NULL
cells	NULL
that	NULL
were	NULL
left	NULL
untreated	NULL
with	NULL
respect	NULL
to	NULL
cells	NULL
treated	NULL
with	NULL
SOF-	NULL
or	NULL
FOS-OLIGO	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

DISCUSSION	NULL
The	NULL
c-Fos	NULL
protein	NULL
is	NULL
a	NULL
component	NULL
of	NULL
the	NULL
AP-1	NULL
transcription	NULL
factor	NULL
complex	NULL
and	NULL
is	NULL
a	NULL
member	NULL
of	NULL
a	NULL
multigene	NULL
family	NULL
,	NULL
including	NULL
the	NULL
fos-related	NULL
(	NULL
fos	NULL
B	NULL
,	NULL
fra-1	NULL
,	NULL
fra-2	NULL
)	NULL
and	NULL
jun-related	NULL
(	NULL
c-jun	NULL
,	NULL
jun	NULL
B	NULL
,	NULL
jun	NULL
D	NULL
)	NULL
genes	NULL
.	NULL

The	NULL
AP-1	NULL
binding	NULL
site	NULL
is	NULL
recog-	NULL
1659	NULL
nized	NULL
by	NULL
dimeric	NULL
protein	NULL
complexes	NULL
composed	NULL
of	NULL
Jun	NULL
homo-dimers	NULL
or	NULL
Fos/Jun	NULL
heterodimers	NULL
.	NULL

The	NULL
Fos/Jun	NULL
heterodimer	NULL
complex	NULL
shows	NULL
greater	NULL
affinity	NULL
than	NULL
Jun/Jun	NULL
homodimer	NULL
for	NULL
the	NULL
AP-1	NULL
binding	NULL
site	NULL
.	NULL
``	NULL

''	NULL
``	NULL
'	NULL
Moreover	NULL
,	NULL
c-Fos	NULL
protein	NULL
can	NULL
also	NULL
heterodimerize	NULL
with	NULL
some	NULL
components	NULL
of	NULL
the	NULL
NF-kB	NULL
``	NULL
or	NULL
ATFE/CREB®	NULL
``	NULL
families	NULL
,	NULL
thus	NULL
allowing	NULL
a	NULL
cross-talk	NULL
between	NULL
different	NULL
transduction	NULL
pathways	NULL
,	NULL
and	NULL
providing	NULL
an	NULL
important	NULL
route	NULL
for	NULL
different	NULL
intracellular	NULL
signals	NULL
to	NULL
be	NULL
integrated	NULL
at	NULL
the	NULL
level	NULL
of	NULL
transcriptional	NULL
control	NULL
.	NULL

Our	NULL
data	NULL
indicate	NULL
that	NULL
the	NULL
transactivator	NULL
Tat	NULL
protein	NULL
of	NULL
HIV-1	NULL
upregulates	NULL
c-fos	NULL
gene	NULL
expression	NULL
in	NULL
both	NULL
activated	NULL
Jurkat	NULL
and	NULL
U937	NULL
cell	NULL
lines	NULL
,	NULL
as	NULL
well	NULL
as	NULL
in	NULL
freshly	NULL
isolated	NULL
activated	NULL
PBMC	NULL
.	NULL

The	NULL
effects	NULL
of	NULL
Tat	NULL
on	NULL
promoter	NULL
activity	NULL
,	NULL
mRNA	NULL
expression	NULL
and	NULL
protein	NULL
synthesis	NULL
suggested	NULL
that	NULL
c-fos	NULL
upregulation	NULL
was	NULL
primarily	NULL
caused	NULL
at	NULL
the	NULL
transcriptional	NULL
level	NULL
.	NULL

Moreover	NULL
,	NULL
the	NULL
structural	NULL
integrity	NULL
of	NULL
the	NULL
activation	NULL
domain	NULL
of	NULL
Tat	NULL
was	NULL
required	NULL
for	NULL
the	NULL
promotion	NULL
of	NULL
the	NULL
c-fos	NULL
promoter	NULL
in	NULL
both	NULL
Jurkat	NULL
and	NULL
U937	NULL
cells	NULL
,	NULL
since	NULL
a	NULL
single	NULL
mutation	NULL
in	NULL
the	NULL
aminoacid	NULL
cys*	NULL
was	NULL
sufficient	NULL
to	NULL
completely	NULL
block	NULL
the	NULL
upregulation	NULL
of	NULL
c-fos	NULL
expression	NULL
.	NULL

Since	NULL
the	NULL
mutation	NULL
in	NULL
cys	NULL
``	NULL
results	NULL
in	NULL
the	NULL
complete	NULL
loss	NULL
of	NULL
the	NULL
transactivating	NULL
activity	NULL
of	NULL
Tat	NULL
on	NULL
HIV-1	NULL
LTR	NULL
,	NULL
*	NULL
our	NULL
findings	NULL
suggest	NULL
that	NULL
Tat-mediated	NULL
activation	NULL
of	NULL
the	NULL
c-fos	NULL
promoter	NULL
and	NULL
the	NULL
HIV-1	NULL
LTR	NULL
are	NULL
likely	NULL
dependent	NULL
on	NULL
the	NULL
same	NULL
Tat	NULL
function	NULL
.	NULL

According	NULL
to	NULL
previous	NULL
findings	NULL
on	NULL
the	NULL
transactivation	NULL
of	NULL
the	NULL
IL-	NULL
Ap	NULL
2	NULL
3	NULL
40	NULL
5	NULL
Bq	NULL
op	NULL
3	NULL
40	NULL
5	NULL
Fig	NULL
6	NULL
.	NULL

-	NULL
Northern	NULL
blot	NULL
analysis	NULL
of	NULL
(	NULL
A	NULL
)	NULL
c-fos	NULL
and	NULL
(	NULL
B	NULL
)	NULL
GAPDH	NULL
mRNA	NULL
in	NULL
Jurkat	NULL
cells	NULL
.	NULL

RNA	NULL
was	NULL
extracted	NULL
from	NULL
cells	NULL
serum-starved	NULL
(	NULL
1	NULL
%	NULL
FCS	NULL
)	NULL
for	NULL
24	NULL
hours	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
and	NULL
then	NULL
treated	NULL
for	NULL
30	NULL
minutes	NULL
with	NULL
15	NULL
%	NULL
FCS	NULL
{	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
15	NULL
%	NULL
FCS	NULL
plus	NULL
recombinant	NULL
p24	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
15	NULL
%	NULL
FCS	NULL
plus	NULL
recombinant	NULL
Tat	NULL
preincubated	NULL
with	NULL
an	NULL
anti-Tat	NULL
MoAb	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
,	NULL
and	NULL
15	NULL
%	NULL
FCS	NULL
plus	NULL
recombinant	NULL
Tat	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
.	NULL

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

1660	NULL
$	NULL
$	NULL
A	NULL
D	NULL
16°	NULL
10	NULL
Toe	NULL
feg	NULL
The	NULL
-	NULL
16°	NULL
108	NULL
102	NULL
10	NULL
``	NULL
10	NULL
``	NULL
a	NULL
$	NULL
B	NULL
E	NULL
Teo	NULL
Th	NULL
7	NULL
TB	NULL
7	NULL
``	NULL
Too	NULL
16	NULL
16	NULL
1b	NULL
1	NULL
:	NULL
GIBELLINI	NULL
ET	NULL
AL	NULL
©	NULL
$	NULL
w	NULL
|	NULL
4	NULL
|	NULL
|	NULL
|	NULL
‘	NULL
10°	NULL
Fig	NULL
7	NULL
.	NULL

-	NULL
Analysis	NULL
of	NULL
c-Fos	NULL
protein	NULL
expression	NULL
by	NULL
indirect	NULL
immunofluorescence	NULL
and	NULL
flow	NULL
cytometry	NULL
in	NULL
Jurkat	NULL
(	NULL
A	NULL
through	NULL
F	NULL
)	NULL
and	NULL
primary	NULL
PBMC	NULL
(	NULL
G	NULL
through	NULL
N	NULL
}	NULL
.	NULL

c-Fos	NULL
protein	NULL
was	NULL
determined	NULL
in	NULL
24-hour	NULL
serum-starved	NULL
cells	NULL
before	NULL
(	NULL
A	NULL
,	NULL
D	NULL
,	NULL
G	NULL
,	NULL
L	NULL
)	NULL
and	NULL
after	NULL
a	NULL
45-minute	NULL
treatment	NULL
with	NULL
15	NULL
%	NULL
FCS	NULL
(	NULL
B	NULL
,	NULL
H	NULL
)	NULL
,	NULL
5	NULL
g	NULL
PHA	NULL
plus	NULL
10~	NULL
'	NULL
mol/L	NULL
PMA	NULL
(	NULL
E	NULL
,	NULL
M	NULL
)	NULL
}	NULL
,	NULL
Tat	NULL
plus	NULL
15	NULL
%	NULL
FCS	NULL
(	NULL
C	NULL
,	NULL
1	NULL
)	NULL
,	NULL
Tat	NULL
plus	NULL
5	NULL
pg	NULL
PHA	NULL
plus	NULL
10~	NULL
'	NULL
mol/L	NULL
PMA	NULL
(	NULL
F	NULL
,	NULL
NJ	NULL
.	NULL

Horizontal	NULL
axis	NULL
,	NULL
relative	NULL
c-Fos	NULL
expression	NULL
detected	NULL
by	NULL
fluorescence	NULL
intensity	NULL
(	NULL
logarithmic	NULL
scale	NULL
)	NULL
.	NULL

Vertical	NULL
axis	NULL
,	NULL
relative	NULL
number	NULL
of	NULL
cells	NULL
.	NULL

Nonspecific	NULL
fluorescence	NULL
{	NULL
not	NULL
shown	NULL
)	NULL
was	NULL
monitored	NULL
by	NULL
staining	NULL
cells	NULL
with	NULL
normal	NULL
rabbit	NULL
serum	NULL
plus	NULL
GAR-FITC	NULL
.	NULL

2	NULL
gene	NULL
mediated	NULL
by	NULL
Tat	NULL
,	NULL
``	NULL
we	NULL
found	NULL
out	NULL
that	NULL
the	NULL
transient	NULL
expression	NULL
of	NULL
tat	NULL
was	NULL
unable	NULL
in	NULL
itself	NULL
to	NULL
enhance	NULL
c-fos	NULL
expression	NULL
in	NULL
either	NULL
tumoral	NULL
or	NULL
primary	NULL
unstimulated	NULL
cells	NULL
;	NULL
however	NULL
,	NULL
Tat	NULL
significantly	NULL
improved	NULL
the	NULL
effect	NULL
of	NULL
other	NULL
stimuli	NULL
such	NULL
as	NULL
high	NULL
serum	NULL
concentrations	NULL
.	NULL

Experiments	NULL
performed	NULL
with	NULL
c-fos	NULL
promoter	NULL
deletion	NULL
mutants	NULL
indicated	NULL
that	NULL
the	NULL
responsive	NULL
region	NULL
required	NULL
for	NULL
Tat	NULL
activity	NULL
was	NULL
set	NULL
between	NULL
-404	NULL
and	NULL
-220	NULL
bp	NULL
and	NULL
that	NULL
the	NULL
SRE	NULL
was	NULL
critical	NULL
for	NULL
Tat	NULL
transactivation	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
c-fos	NULL
activation	NULL
mediated	NULL
by	NULL
Tat	NULL
revealed	NULL
both	NULL
clear	NULL
differences	NULL
and	NULL
definite	NULL
similarities	NULL
with	NULL
the	NULL
c-fos	NULL
transactivation	NULL
induced	NULL
by	NULL
the	NULL
transactivating	NULL
Tax	NULL
protein	NULL
of	NULL
HTLV-1	NULL
.	NULL
``	NULL

Both	NULL
transactivators	NULL
synergized	NULL
with	NULL
high	NULL
serum	NULL
concentra-tions	NULL
,	NULL
PHA	NULL
or	NULL
PMA	NULL
in	NULL
stimulating	NULL
c-fos	NULL
gene	NULL
expression	NULL
.	NULL

Moreover	NULL
,	NULL
the	NULL
analysis	NULL
of	NULL
deletion	NULL
mutants	NULL
underlined	NULL
the	NULL
central	NULL
role	NULL
of	NULL
SRE	NULL
in	NULL
the	NULL
transactivation	NULL
activity	NULL
of	NULL
both	NULL
Tat	NULL
and	NULL
Tax	NULL
.	NULL

However	NULL
,	NULL
Tax	NULL
is	NULL
a	NULL
stronger	NULL
inducer	NULL
of	NULL
c-fos	NULL
expression	NULL
,	NULL
as	NULL
it	NULL
is	NULL
able	NULL
to	NULL
transactivate	NULL
c-fos	NULL
promoter	NULL
even	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
low	NULL
serum	NULL
concentration	NULL
.	NULL

The	NULL
mechanism	NULL
by	NULL
which	NULL
Tat	NULL
affects	NULL
c-fos	NULL
gene	NULL
expression	NULL
remains	NULL
to	NULL
be	NULL
fully	NULL
elucidated	NULL
.	NULL

Bulge	NULL
(	NULL
AUCUG	NULL
)	NULL
and	NULL
stem-loop	NULL
(	NULL
CUGGGA	NULL
)	NULL
structures	NULL
similar	NULL
to	NULL
the	NULL
Tat-binding	NULL
site	NULL
on	NULL
HIV-1	NULL
LTR	NULL
RNA	NULL
have	NULL
been	NULL
identified	NULL
downstream	NULL
of	NULL
the	NULL
transcriptional	NULL
start	NULL
site	NULL
of	NULL
the	NULL
tumor	NULL
necrosis	NULL
factor-B	NULL
``	NULL
and	NULL
JC	NULL
virus	NULL
``	NULL
``	NULL
promoters	NULL
,	NULL
and	NULL
have	NULL
been	NULL
implicated	NULL
in	NULL
the	NULL
Tat-induced	NULL
activation	NULL
of	NULL
these	NULL
genes	NULL
.	NULL

However	NULL
,	NULL
sequence	NULL
comparison	NULL
of	NULL
the	NULL
c-fos	NULL
mRNA	NULL
and	NULL
TAR	NULL
revealed	NULL
no	NULL
similarities	NULL
between	NULL
the	NULL
TAR	NULL
region	NULL
of	NULL
LTR	NULL
and	NULL
c-fos	NULL
mRNA	NULL
.	NULL

Similarly	NULL
,	NULL
other	NULL
authors	NULL
failed	NULL
show	NULL
the	NULL
presence	NULL
of	NULL
stem-loop	NULL
sequences	NULL
in	NULL
different	NULL
cellular	NULL
genes	NULL
activated	NULL
by	NULL
Tat	NULL
.	NULL
``	NULL

*	NULL
``	NULL
Therefore	NULL
,	NULL
the	NULL
transactivation	NULL
of	NULL
c-fos	NULL
gene	NULL
expression	NULL
may	NULL
be	NULL
the	NULL
consequence	NULL
of	NULL
a	NULL
TAR-independent	NULL
mechanism	NULL
of	NULL
transcriptional	NULL
activation	NULL
mediated	NULL
by	NULL
Tat	NULL
.	NULL

Moreover	NULL
,	NULL
the	NULL
ability	NULL
of	NULL
Tat	NULL
to	NULL
enhance	NULL
c-fos	NULL
transcription	NULL
only	NULL
when	NULL
additional	NULL
stimuli	NULL
are	NULL
present	NULL
,	NULL
suggests	NULL
a	NULL
primary	NULL
role	NULL
in	NULL
elongation	NULL
and	NULL
transcription	NULL
processivity	NULL
rather	NULL
than	NULL
in	NULL
the	NULL
transcription	NULL
initiation	NULL
of	NULL
c-fos	NULL
gene	NULL
,	NULL
as	NULL
previously	NULL
described	NULL
for	NULL
the	NULL
HIV-1	NULL
LTR	NULL
.	NULL

It	NULL
is	NULL
remarkable	NULL
that	NULL
even	NULL
in	NULL
its	NULL
extracellular	NULL
form	NULL
Tat	NULL
was	NULL
able	NULL
to	NULL
upregulate	NULL
c-fos	NULL
expression	NULL
in	NULL
activated	NULL
primary	NULL
and	NULL
tumoral	NULL
cells	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
extracellular	NULL
Tat	NULL
may	NULL
imply	NULL
the	NULL
uptake	NULL
and	NULL
nuclear	NULL
localization	NULL
of	NULL
Tat	NULL
protein	NULL
,	NULL
``	NULL
``	NULL
which	NULL
may	NULL
From	NULL
UPREGULATION	NULL
OF	NULL
C-FOS	NULL
BY	NULL
TAT	NULL
Fig	NULL
8	NULL
.	NULL

-	NULL
Analysis	NULL
of	NULL
c-Fos	NULL
protein	NULL
performed	NULL
in	NULL
Jurkat	NULL
cells	NULL
by	NULL
indirect	NULL
immunofluorescence	NULL
and	NULL
revealed	NULL
by	NULL
confocal	NULL
microscopy	NULL
.	NULL

The	NULL
presence	NULL
of	NULL
c-Fos	NULL
was	NULL
evaluated	NULL
in	NULL
24-hour	NULL
serum-starved	NULL
cells	NULL
before	NULL
(	NULL
A	NULL
)	NULL
and	NULL
after	NULL
a	NULL
45-minute	NULL
treatment	NULL
with	NULL
15	NULL
%	NULL
FCS	NULL
(	NULL
B	NULL
)	NULL
or	NULL
Tat	NULL
plus	NULL
15	NULL
%	NULL
FCS	NULL
(	NULL
C	NULL
)	NULL
.	NULL

by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

1661	NULL
act	NULL
directly	NULL
on	NULL
c-fos	NULL
promoter	NULL
.	NULL

Alternatively	NULL
,	NULL
extracellular	NULL
Tat	NULL
might	NULL
trigger	NULL
an	NULL
intracellular	NULL
signal	NULL
transduction	NULL
pathway	NULL
after	NULL
specific	NULL
membrane	NULL
interactions	NULL
with	NULL
different	NULL
types	NULL
of	NULL
integrin	NULL
receptors	NULL
present	NULL
on	NULL
those	NULL
cells	NULL
sensitive	NULL
to	NULL
its	NULL
biological	NULL
activity	NULL
.	NULL
``	NULL

''	NULL
``	NULL
``	NULL
``	NULL
``	NULL
A	NULL
similar	NULL
mechanism	NULL
has	NULL
been	NULL
proposed	NULL
to	NULL
explain	NULL
the	NULL
Tat-induced	NULL
proliferation	NULL
of	NULL
Kaposi	NULL
's	NULL
sarcoma	NULL
spindle	NULL
cells	NULL
and	NULL
normal	NULL
endothelial	NULL
cells	NULL
preacti-vated	NULL
by	NULL
cytokines	NULL
.	NULL
``	NULL

If	NULL
this	NULL
model	NULL
is	NULL
correct	NULL
,	NULL
extracellular	NULL
Tat	NULL
could	NULL
mimic	NULL
the	NULL
effect	NULL
of	NULL
extracellular	NULL
matrix	NULL
proteins	NULL
activating	NULL
c-fos	NULL
expression	NULL
through	NULL
an	NULL
intracellular	NULL
signal	NULL
cascade	NULL
.	NULL
``	NULL

Our	NULL
data	NULL
indicate	NULL
that	NULL
c-Fos	NULL
induction	NULL
by	NULL
Tat	NULL
may	NULL
have	NULL
a	NULL
role	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
HIV-1	NULL
LTR	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
SOF-OLIGO	NULL
significantly	NULL
inhibited	NULL
CAT	NULL
activity	NULL
in	NULL
both	NULL
Jurkat	NULL
and	NULL
U937	NULL
cells	NULL
transiently	NULL
transfected	NULL
with	NULL
tat/S	NULL
and	NULL
an	NULL
LTR-CAT	NULL
reporter	NULL
plasmid	NULL
,	NULL
and	NULL
were	NULL
able	NULL
to	NULL
specifically	NULL
decrease	NULL
the	NULL
gag	NULL
p24	NULL
levels	NULL
in	NULL
the	NULL
culture	NULL
supernatants	NULL
of	NULL
either	NULL
Jurkat	NULL
cells	NULL
or	NULL
primary	NULL
PBMC	NULL
acutely	NULL
infected	NULL
with	NULL
HIV-1	NULL
.	NULL

The	NULL
upregulation	NULL
of	NULL
c-Fos	NULL
induced	NULL
by	NULL
Tat	NULL
may	NULL
influence	NULL
HIV-1	NULL
genome	NULL
expression	NULL
and	NULL
HIV-1	NULL
replication	NULL
in	NULL
several	NULL
ways	NULL
.	NULL

Firstly	NULL
,	NULL
the	NULL
activation	NULL
of	NULL
c-Fos	NULL
contributes	NULL
to	NULL
cell	NULL
cycle	NULL
progression	NULL
of	NULL
hematopoietic	NULL
cells	NULL
,	NULL
acting	NULL
throughout	NULL
all	NULL
the	NULL
phases	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL
``	NULL

''	NULL
In	NULL
this	NULL
respect	NULL
,	NULL
it	NULL
has	NULL
been	NULL
established	NULL
that	NULL
HIV-1	NULL
infects	NULL
more	NULL
efficiently	NULL
activated	NULL
cells	NULL
than	NULL
the	NULL
quiescent	NULL
ones	NULL
.	NULL
``	NULL

Secondly	NULL
,	NULL
transcriptional	NULL
studies	NULL
of	NULL
the	NULL
HIV-1	NULL
genome	NULL
have	NULL
shown	NULL
that	NULL
the	NULL
HIV-1	NULL
LTR	NULL
promoter	NULL
can	NULL
be	NULL
subdivided	NULL
into	NULL
three	NULL
functional	NULL
domains	NULL
:	NULL
a	NULL
basal	NULL
core	NULL
promoter	NULL
,	NULL
which	NULL
is	NULL
made	NULL
up	NULL
by	NULL
the	NULL
transcriptional	NULL
start	NULL
site	NULL
,	NULL
a	NULL
TATA	NULL
box	NULL
,	NULL
and	NULL
three	NULL
tandem	NULL
Spl	NULL
binding	NULL
sites	NULL
(	NULL
GC-boxes	NULL
)	NULL
;	NULL
an	NULL
upstream	NULL
enhancer	NULL
element	NULL
containing	NULL
two	NULL
adjacent	NULL
binding	NULL
sites	NULL
for	NULL
nuclear	NULL
factor	NULL
<	NULL
B	NULL
(	NULL
NFkB	NULL
)	NULL
;	NULL
a	NULL
far	NULL
upstream	NULL
modulatory	NULL
region	NULL
.	NULL
``	NULL

The	NULL
HIV-1	NULL
LTR	NULL
promoter	NULL
also	NULL
contains	NULL
AP-1	NULL
motifs	NULL
both	NULL
upstream	NULL
'	NULL
and	NULL
downstream	NULL
``	NULL
of	NULL
the	NULL
transcriptional	NULL
start	NULL
site	NULL
.	NULL

These	NULL
AP-1	NULL
sites	NULL
can	NULL
function	NULL
independently	NULL
of	NULL
or	NULL
in	NULL
concert	NULL
with	NULL
the	NULL
enhancer	NULL
to	NULL
activate	NULL
HIV-1	NULL
transcription	NULL
.	NULL

Moreover	NULL
,	NULL
a	NULL
functional	NULL
and	NULL
physical	NULL
interplay	NULL
of	NULL
tat/s	NULL
+	NULL
SOF-OLIGO	NULL
tat/	NULL
$	NULL
+	NULL
FOS-OLIGO	NULL
tat/	NULL
$	NULL
cDNA	NULL
TC	NULL
I	NULL
I	NULL
T	NULL
T	NULL
t	NULL
0	NULL
20	NULL
40	NULL
60	NULL
8	NULL
0	NULL
100	NULL
LTR-CAT	NULL
activation	NULL
(	NULL
folds	NULL
)	NULL
Fig	NULL
9	NULL
.	NULL

-	NULL
Inhibition	NULL
of	NULL
the	NULL
Tat-mediated	NULL
transactivation	NULL
of	NULL
HIV-1	NULL
LTR-CAT	NULL
by	NULL
SOF-OLIGO	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
,	NULL
activated	NULL
by	NULL
15	NULL
%	NULL
FCS	NULL
24	NULL
hours	NULL
after	NULL
serum-starvation	NULL
(	NULL
1	NULL
%	NULL
FCS	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
transiently	NULL
cotransfected	NULL
with	NULL
LTR-CAT	NULL
plus	NULL
fat/S	NULL
plus	NULL
SOF-OLIGO	NULL
or	NULL
FOS-OLIGO	NULL
.	NULL

CAT	NULL
activity	NULL
is	NULL
expressed	NULL
as	NULL
folds	NULL
of	NULL
activation	NULL
with	NULL
respect	NULL
to	NULL
Jurkat	NULL
cells	NULL
transfected	NULL
with	NULL
LTR-CAT	NULL
alone	NULL
.	NULL

Data	NULL
are	NULL
reported	NULL
as	NULL
means	NULL
+	NULL
SDs	NULL
of	NULL
three	NULL
independent	NULL
transfection	NULL
experiments	NULL
performed	NULL
in	NULL
duplicate	NULL
.	NULL

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

1662	NULL
Jurkat	NULL
--	NULL
O-	NULL
_	NULL
untreated	NULL
cultures	NULL
--	NULL
&	NULL
~	NULL
--	NULL
-	NULL
SOF-OLIGO	NULL
--	NULL
-	NULL
_	NULL
FOS-OLIGO	NULL
ha	NULL
&	NULL
&	NULL
O	NULL
i	NULL
gag	NULL
p24	NULL
level	NULL
(	NULL
pg/ml	NULL
)	NULL
To	NULL
gag	NULL
p24	NULL
levels	NULL
(	NULL
pg/ml	NULL
)	NULL
Days	NULL
of	NULL
culture	NULL
Fig	NULL
10	NULL
.	NULL

-	NULL
Quantitative	NULL
levels	NULL
of	NULL
gag	NULL
p24	NULL
levels	NULL
in	NULL
the	NULL
culture	NULL
supernatants	NULL
of	NULL
(	NULL
A	NULL
)	NULL
Jurkat	NULL
cells	NULL
and	NULL
(	NULL
B	NULL
)	NULL
PBMC	NULL
acutely	NULL
infected	NULL
with	NULL
HIV-1	NULL
{	NULL
IIB	NULL
)	NULL
and	NULL
then	NULL
cultured	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
25	NULL
mol/L	NULL
SOF-OLIGO	NULL
or	NULL
FOS-OLIGO	NULL
added	NULL
every	NULL
other	NULL
day	NULL
.	NULL

Data	NULL
are	NULL
reported	NULL
as	NULL
means	NULL
+	NULL
SDs	NULL
of	NULL
three	NULL
independent	NULL
transfection	NULL
experiments	NULL
performed	NULL
in	NULL
duplicate	NULL
.	NULL

the	NULL
AP-1	NULL
and	NULL
NF-kB	NULL
families	NULL
of	NULL
transcription	NULL
factors	NULL
has	NULL
recently	NULL
been	NULL
described	NULL
.	NULL
``	NULL

In	NULL
conclusion	NULL
,	NULL
we	NULL
have	NULL
clearly	NULL
shown	NULL
that	NULL
HIV-1	NULL
transactivating	NULL
Tat	NULL
protein	NULL
upregulates	NULL
the	NULL
expression	NULL
of	NULL
c-fos	NULL
gene	NULL
and	NULL
the	NULL
enhanced	NULL
c-Fos	NULL
protein	NULL
production	NULL
may	NULL
represent	NULL
an	NULL
important	NULL
intermediate	NULL
step	NULL
for	NULL
the	NULL
Tat-dependent	NULL
HIV-1	NULL
genome	NULL
transactivation	NULL
.	NULL

In	NULL
the	NULL
light	NULL
of	NULL
the	NULL
positive	NULL
synergy	NULL
between	NULL
NF-	NULL
«	NULL
B	NULL
p65	NULL
and	NULL
c-Fos	NULL
,	NULL
the	NULL
ability	NULL
of	NULL
Tat	NULL
to	NULL
stimulate	NULL
both	NULL
factors	NULL
has	NULL
important	NULL
implications	NULL
for	NULL
the	NULL
promotion	NULL
of	NULL
viral	NULL
replication	NULL
,	NULL
and	NULL
,	NULL
possibly	NULL
,	NULL
for	NULL
the	NULL
control	NULL
of	NULL
both	NULL
immune	NULL
and	NULL
inflammatory	NULL
responses	NULL
through	NULL
the	NULL
production	NULL
of	NULL
various	NULL
cytokines	NULL
.	NULL

In	NULL
an	NULL
evolutionary	NULL
perspective	NULL
,	NULL
it	NULL
may	NULL
provide	NULL
the	NULL
virus	NULL
with	NULL
a	NULL
mechanism	NULL
to	NULL
broaden	NULL
its	NULL
LTR	NULL
response	NULL
to	NULL
extracellular	NULL
stimuli	NULL
and	NULL
activate	NULL
viral	NULL
gene	NULL
transcription	NULL
under	NULL
a	NULL
wide	NULL
variety	NULL
of	NULL
cellular	NULL
conditions	NULL
.	NULL

Functional	NULL
redundancy	NULL
is	NULL
a	NULL
common	NULL
feature	NULL
of	NULL
viral	NULL
as	NULL
well	NULL
as	NULL
cellular	NULL
regulatory	NULL
regions	NULL
and	NULL
in	NULL
this	NULL
case	NULL
it	NULL
may	NULL
represent	NULL
a	NULL
mechanism	NULL
to	NULL
increase	NULL
virus	NULL
host	NULL
range	NULL
and	NULL
virus	NULL
replication	NULL
potentiality	NULL
.	NULL

ACKNOWLEDGMENT	NULL
We	NULL
are	NULL
grateful	NULL
to	NULL
Dr	NULL
Paolo	NULL
Sassone-Corsi	NULL
for	NULL
providing	NULL
all	NULL
the	NULL
c-fos/CAT	NULL
plasmids	NULL
and	NULL
to	NULL
Dr	NULL
Enzo	NULL
Lalli	NULL
for	NULL
helpfull	NULL
discussion	NULL
.	NULL

GIBELLINI	NULL
ET	NULL
AL	NULL
This	NULL
research	NULL
was	NULL
supported	NULL
by	NULL
``	NULL
AIDS	NULL
project'*	NULL
of	NULL
the	NULL
Italian	NULL
Ministry	NULL
of	NULL
Health	NULL
and	NULL
MURST	NULL
40	NULL
and	NULL
60	NULL
%	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Jones	NULL
KA	NULL
,	NULL
Peterlin	NULL
MB	NULL
:	NULL
Control	NULL
of	NULL
RNA	NULL
initiation	NULL
and	NULL
elongation	NULL
at	NULL
the	NULL
HIV-1	NULL
promoter	NULL
.	NULL

Annu	NULL
Rev	NULL
Biochem	NULL
63:717	NULL
,	NULL
1994	NULL
2	NULL
.	NULL

Koken	NULL
SEC	NULL
,	NULL
Greijer	NULL
AB	NULL
,	NULL
Verhoef	NULL
K	NULL
,	NULL
van	NULL
Wamel	NULL
J	NULL
,	NULL
Bukrin-skaya	NULL
AG	NULL
,	NULL
Berkout	NULL
B	NULL
:	NULL
Intracellular	NULL
analysis	NULL
of	NULL
in	NULL
vitro	NULL
modified	NULL
HIV	NULL
Tat	NULL
protein	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
269:8366	NULL
,	NULL
1994	NULL
3	NULL
.	NULL

Dang	NULL
CV	NULL
,	NULL
Lee	NULL
WMF	NULL
:	NULL
Nuclear	NULL
and	NULL
nucleolar	NULL
targeting	NULL
sequences	NULL
of	NULL
c-erb-A	NULL
,	NULL
c-myc	NULL
,	NULL
N-myc	NULL
,	NULL
p53	NULL
,	NULL
HPS70	NULL
,	NULL
and	NULL
HIV	NULL
tat	NULL
proteins	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
264:18019	NULL
,	NULL
1989	NULL
4	NULL
.	NULL

Dingwall	NULL
C	NULL
,	NULL
Emberg	NULL
I	NULL
,	NULL
Gait	NULL
MJ	NULL
,	NULL
Green	NULL
SM	NULL
,	NULL
Heaphy	NULL
S	NULL
,	NULL
Karn	NULL
J	NULL
,	NULL
Lowe	NULL
AD	NULL
,	NULL
Singh	NULL
M	NULL
,	NULL
Skinner	NULL
MA	NULL
,	NULL
Valerio	NULL
R	NULL
:	NULL
HIV-1	NULL
tat	NULL
protein	NULL
binds	NULL
transactivation-response	NULL
region	NULL
(	NULL
TAR	NULL
)	NULL
in	NULL
vitro	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
86:6925	NULL
,	NULL
1989	NULL
5	NULL
.	NULL

Cullen	NULL
BR	NULL
:	NULL
Regulation	NULL
of	NULL
HIV-1	NULL
gene	NULL
expression	NULL
.	NULL

FASEB	NULL
J	NULL
5:2361	NULL
,	NULL
1991	NULL
6	NULL
.	NULL

Taylor	NULL
JP	NULL
,	NULL
Kundu	NULL
M	NULL
,	NULL
Khalili	NULL
K	NULL
:	NULL
TAR-independent	NULL
activation	NULL
of	NULL
HIV-1	NULL
requires	NULL
the	NULL
activation	NULL
domain	NULL
but	NULL
not	NULL
the	NULL
RNA-binding	NULL
domain	NULL
of	NULL
Tat	NULL
.	NULL

Virology	NULL
195:780	NULL
,	NULL
1993	NULL
7	NULL
.	NULL

Huang	NULL
L	NULL
,	NULL
Joshi	NULL
A	NULL
,	NULL
Willey	NULL
R	NULL
,	NULL
Orenstein	NULL
J	NULL
,	NULL
Jeang	NULL
KT	NULL
:	NULL
Human	NULL
immunodeficiency	NULL
viruses	NULL
regulated	NULL
by	NULL
alternative	NULL
trans-activators	NULL
:	NULL
Genetic	NULL
evidence	NULL
for	NULL
a	NULL
novel	NULL
non-transcriptional	NULL
function	NULL
of	NULL
Tat	NULL
in	NULL
virion	NULL
infectivity	NULL
.	NULL

EMBO	NULL
J	NULL
13:2886	NULL
,	NULL
1994	NULL
8	NULL
.	NULL

Albini	NULL
A	NULL
,	NULL
Fontanini	NULL
G	NULL
,	NULL
Masiello	NULL
L	NULL
,	NULL
Tacchetti	NULL
C	NULL
,	NULL
Bigini	NULL
D	NULL
,	NULL
Luzzi	NULL
P	NULL
,	NULL
Noonan	NULL
DM	NULL
,	NULL
Stetler-Stevenson	NULL
WG	NULL
:	NULL
Angiogenic	NULL
potential	NULL
in	NULL
vivo	NULL
by	NULL
Kaposi	NULL
's	NULL
sarcoma	NULL
cell-free	NULL
supernatants	NULL
and	NULL
HIV-1	NULL
tat	NULL
product	NULL
:	NULL
Inhibition	NULL
of	NULL
KS-like	NULL
lesions	NULL
by	NULL
tissue	NULL
inhibitor	NULL
of	NULL
metallo-proteinase-2	NULL
.	NULL

AIDS	NULL
8:1237	NULL
,	NULL
1994	NULL
9	NULL
.	NULL

Ensoli	NULL
B	NULL
,	NULL
Barillari	NULL
G	NULL
,	NULL
Zaki	NULL
Salahuddin	NULL
S	NULL
,	NULL
Gallo	NULL
RC	NULL
,	NULL
Wong-Stall	NULL
F	NULL
:	NULL
Tat	NULL
protein	NULL
of	NULL
HIV-1	NULL
stimulates	NULL
growth	NULL
of	NULL
cells	NULL
derived	NULL
from	NULL
Kaposi	NULL
's	NULL
sarcoma	NULL
lesions	NULL
of	NULL
AIDS	NULL
patients	NULL
.	NULL

Nature	NULL
345:84	NULL
,	NULL
1990	NULL
10	NULL
.	NULL

Zauli	NULL
G	NULL
,	NULL
Gibellini	NULL
D	NULL
,	NULL
Milani	NULL
D	NULL
,	NULL
Mazzoni	NULL
M	NULL
,	NULL
Borgatti	NULL
P	NULL
,	NULL
La	NULL
Placa	NULL
M	NULL
,	NULL
Capitani	NULL
S	NULL
:	NULL
Human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
Tat	NULL
protein	NULL
protects	NULL
lymphoid	NULL
,	NULL
epithelial	NULL
,	NULL
and	NULL
neuronal	NULL
cell	NULL
lines	NULL
from	NULL
death	NULL
by	NULL
apoptosis	NULL
.	NULL

Cancer	NULL
Res	NULL
53:4481	NULL
,	NULL
1993	NULL
11	NULL
.	NULL

Viscidi	NULL
RP	NULL
,	NULL
Mayur	NULL
K	NULL
,	NULL
Lederman	NULL
HM	NULL
,	NULL
Frankel	NULL
AD	NULL
:	NULL
Inhibition	NULL
of	NULL
antigen-induced	NULL
lymphocyte	NULL
proliferation	NULL
by	NULL
tat	NULL
protein	NULL
from	NULL
HIV-1	NULL
.	NULL

Science	NULL
246:1606	NULL
,	NULL
1989	NULL
12	NULL
.	NULL

Subramanyam	NULL
M	NULL
,	NULL
Gutheil	NULL
WG	NULL
,	NULL
Bachovehin	NULL
WW	NULL
,	NULL
Huber	NULL
BT	NULL
:	NULL
Mechanism	NULL
of	NULL
HIV-1	NULL
Tat	NULL
induced	NULL
inhibition	NULL
of	NULL
antigen-specific	NULL
T	NULL
cell	NULL
responsiveness	NULL
.	NULL

J	NULL
Immunol	NULL
150:2544	NULL
,	NULL
1993	NULL
13	NULL
.	NULL

Chirmule	NULL
N	NULL
,	NULL
Than	NULL
S	NULL
$	NULL
,	NULL
Khan	NULL
S	NULL
,	NULL
Pahwa	NULL
S	NULL
:	NULL
Human	NULL
immunodeficiency	NULL
virus	NULL
Tat	NULL
induces	NULL
functional	NULL
unresponsiveness	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

J	NULL
Virol	NULL
69:492	NULL
,	NULL
1995	NULL
14	NULL
.	NULL

Li	NULL
CJ	NULL
,	NULL
Friedman	NULL
DJ	NULL
,	NULL
Wang	NULL
C	NULL
,	NULL
Metelev	NULL
V	NULL
,	NULL
Pardee	NULL
AB	NULL
:	NULL
Induction	NULL
of	NULL
apoptosis	NULL
in	NULL
uninfected	NULL
lymphocytes	NULL
by	NULL
HIV-1	NULL
Tat	NULL
protein	NULL
.	NULL

Science	NULL
268:229	NULL
,	NULL
1995a	NULL
15	NULL
.	NULL

Westendorp	NULL
MO	NULL
,	NULL
Frank	NULL
R	NULL
,	NULL
Ochsenbauer	NULL
C	NULL
,	NULL
Stricker	NULL
K	NULL
,	NULL
Dhein	NULL
J	NULL
,	NULL
Walczak	NULL
H	NULL
,	NULL
Debatin	NULL
KM	NULL
,	NULL
Krammer	NULL
PH	NULL
:	NULL
Sensitization	NULL
of	NULL
T	NULL
cells	NULL
to	NULL
CD95-mediated	NULL
apoptosis	NULL
by	NULL
HIV-1	NULL
Tat	NULL
and	NULL
gp120	NULL
.	NULL

Nature	NULL
375:497	NULL
,	NULL
1995	NULL
16	NULL
.	NULL

Purvis	NULL
SF	NULL
,	NULL
Jacobberger	NULL
JW	NULL
,	NULL
Sramkoski	NULL
RM	NULL
,	NULL
Patki	NULL
AH	NULL
,	NULL
Lederman	NULL
MM	NULL
:	NULL
HIV	NULL
type	NULL
1	NULL
Tat	NULL
protein	NULL
induces	NULL
apoptosis	NULL
and	NULL
death	NULL
in	NULL
Jurkat	NULL
cells	NULL
.	NULL

AIDS	NULL
Res	NULL
Hum	NULL
Retroviruses	NULL
11:443	NULL
,	NULL
1995	NULL
17	NULL
.	NULL

Vellutini	NULL
C	NULL
,	NULL
Horschowski	NULL
N	NULL
,	NULL
Philippon	NULL
V	NULL
,	NULL
Gambarelli	NULL
D	NULL
,	NULL
Nave	NULL
KA	NULL
,	NULL
Filippi	NULL
P	NULL
:	NULL
Development	NULL
of	NULL
lymphoid	NULL
hyperplasia	NULL
in	NULL
transgenic	NULL
mice	NULL
expressing	NULL
the	NULL
HIV	NULL
tat	NULL
gene	NULL
.	NULL

AIDS	NULL
Res	NULL
Hum	NULL
Retroviruses	NULL
11:21	NULL
,	NULL
1995	NULL
18	NULL
.	NULL

Mace	NULL
K	NULL
,	NULL
Gazzolo	NULL
L	NULL
:	NULL
Expression	NULL
of	NULL
the	NULL
Tat	NULL
protein	NULL
of	NULL
HIV1	NULL
in	NULL
human	NULL
promonocytic	NULL
U937	NULL
cells	NULL
.	NULL

Res	NULL
Virol	NULL
144:27	NULL
,	NULL
1993	NULL
19	NULL
.	NULL

Flores	NULL
SC	NULL
,	NULL
Marecki	NULL
JC	NULL
,	NULL
Harper	NULL
KP	NULL
,	NULL
Bose	NULL
SK	NULL
,	NULL
Nelson	NULL
SK	NULL
,	NULL
McCord	NULL
JM	NULL
:	NULL
Tat	NULL
protein	NULL
of	NULL
HIV-1	NULL
represses	NULL
expression	NULL
of	NULL
manga-	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

UPREGULATION	NULL
OF	NULL
C-FOS	NULL
BY	NULL
TAT	NULL
nese	NULL
superoxide	NULL
dismutase	NULL
in	NULL
HeLa	NULL
cells	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
90:7632	NULL
,	NULL
1993	NULL
20	NULL
.	NULL

Longo	NULL
F	NULL
,	NULL
Marchetti	NULL
MA	NULL
,	NULL
Castagnoli	NULL
L	NULL
,	NULL
Battaglia	NULL
PA	NULL
,	NULL
Gigliani	NULL
F	NULL
:	NULL
A	NULL
novel	NULL
approach	NULL
to	NULL
protein-protein	NULL
interaction	NULL
:	NULL
Complex	NULL
formation	NULL
between	NULL
p53	NULL
tumor	NULL
suppressor	NULL
and	NULL
the	NULL
HIV	NULL
Tat	NULL
proteins	NULL
.	NULL

Biochem	NULL
Biophys	NULL
Res	NULL
Commun	NULL
206:326	NULL
,	NULL
1995	NULL
21	NULL
.	NULL

Li	NULL
CJ	NULL
,	NULL
Wang	NULL
C	NULL
,	NULL
Friedman	NULL
DJ	NULL
,	NULL
Pardee	NULL
AB	NULL
:	NULL
Reciprocal	NULL
modulations	NULL
between	NULL
p53	NULL
and	NULL
Tat	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
92:5461	NULL
,	NULL
1995b	NULL
22	NULL
.	NULL

Westendorp	NULL
MO	NULL
,	NULL
Shatrov	NULL
VA	NULL
,	NULL
Schulze-Osthoff	NULL
K	NULL
,	NULL
Frank	NULL
R	NULL
,	NULL
Kraft	NULL
M	NULL
,	NULL
Los	NULL
M	NULL
,	NULL
Krammer	NULL
PH	NULL
,	NULL
Droge	NULL
W	NULL
,	NULL
Lehmann	NULL
V	NULL
:	NULL
HIV-1	NULL
Tat	NULL
potentiates	NULL
TNF-induced	NULL
activation	NULL
and	NULL
cytotoxicity	NULL
by	NULL
altering	NULL
the	NULL
cellular	NULL
redox	NULL
state	NULL
.	NULL

EMBO	NULL
J	NULL
14:546	NULL
,	NULL
1995	NULL
23	NULL
.	NULL

Zauli	NULL
G	NULL
,	NULL
Davis	NULL
BR	NULL
,	NULL
Re	NULL
MC	NULL
,	NULL
Visani	NULL
G	NULL
,	NULL
Furlini	NULL
G	NULL
,	NULL
La	NULL
Placa	NULL
M	NULL
:	NULL
Tat	NULL
protein	NULL
stimulates	NULL
production	NULL
of	NULL
transforming	NULL
growth	NULL
factor-B1	NULL
by	NULL
marrow	NULL
macrophages	NULL
:	NULL
A	NULL
potential	NULL
mechanism	NULL
for	NULL
HIV-1	NULL
induced	NULL
hematopoietic	NULL
suppression	NULL
.	NULL

Blood	NULL
80:3036	NULL
,	NULL
1992	NULL
24	NULL
.	NULL

Buonaguro	NULL
L	NULL
,	NULL
Barillari	NULL
G	NULL
,	NULL
Chang	NULL
HK	NULL
,	NULL
Bohan	NULL
CA	NULL
,	NULL
Kao	NULL
V	NULL
,	NULL
Morgan	NULL
R	NULL
,	NULL
Gallo	NULL
RC	NULL
,	NULL
Ensoli	NULL
B	NULL
:	NULL
Effects	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
Tat	NULL
protein	NULL
on	NULL
the	NULL
expression	NULL
of	NULL
inflammatory	NULL
cytokine	NULL
.	NULL

J	NULL
Virol	NULL
66:7159	NULL
,	NULL
1992	NULL
25	NULL
.	NULL

Purvis	NULL
SF	NULL
,	NULL
Georges	NULL
DL	NULL
,	NULL
Williams	NULL
TM	NULL
,	NULL
Lederman	NULL
MM	NULL
:	NULL
Suppression	NULL
of	NULL
interleukin-2	NULL
and	NULL
interleukin-2	NULL
receptor	NULL
expression	NULL
in	NULL
Jurkat	NULL
cells	NULL
stably	NULL
expressing	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
Tat	NULL
protein	NULL
.	NULL

Cell	NULL
Immunol	NULL
144:32	NULL
,	NULL
1992	NULL
26	NULL
.	NULL

Scala	NULL
G	NULL
,	NULL
Ruocco	NULL
MR	NULL
,	NULL
Ambrosino	NULL
C	NULL
,	NULL
Mallardo	NULL
M	NULL
,	NULL
Giordano	NULL
V	NULL
,	NULL
Baldassarre	NULL
F	NULL
,	NULL
Dragonetti	NULL
E	NULL
,	NULL
Quinto	NULL
I	NULL
,	NULL
Venuta	NULL
S	NULL
:	NULL
The	NULL
expression	NULL
of	NULL
the	NULL
interleukin	NULL
6	NULL
gene	NULL
is	NULL
induced	NULL
by	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
1	NULL
tat	NULL
protein	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
179:961	NULL
,	NULL
1994	NULL
27	NULL
.	NULL

Gibellini	NULL
D	NULL
,	NULL
Zauli	NULL
G	NULL
,	NULL
Re	NULL
MC	NULL
,	NULL
Milani	NULL
D	NULL
,	NULL
Furlini	NULL
G	NULL
,	NULL
Caramelli	NULL
E	NULL
,	NULL
Capitani	NULL
S	NULL
,	NULL
La	NULL
Placa	NULL
M	NULL
:	NULL
Recombinant	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type-1	NULL
(	NULL
HIV-1	NULL
)	NULL
Tat	NULL
protein	NULL
sequentially	NULL
upregulates	NULL
IL-6	NULL
and	NULL
mRNA	NULL
expression	NULL
and	NULL
protein	NULL
synthesis	NULL
in	NULL
peripheral	NULL
blood	NULL
monocytes	NULL
.	NULL

Br	NULL
J	NULL
Haematol	NULL
88:261	NULL
,	NULL
1988	NULL
28	NULL
.	NULL

Westendorp	NULL
MO	NULL
,	NULL
Li-Weber	NULL
M	NULL
,	NULL
Frank	NULL
RW	NULL
,	NULL
Krammer	NULL
PH	NULL
:	NULL
Human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
Tat	NULL
upregulates	NULL
interleukin-2	NULL
secretion	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
.	NULL

J	NULL
Virol	NULL
68:4177	NULL
,	NULL
1994	NULL
29	NULL
.	NULL

Zauli	NULL
G	NULL
,	NULL
Gibellini	NULL
D	NULL
,	NULL
Caputo	NULL
A	NULL
,	NULL
Bassini	NULL
A	NULL
,	NULL
Negrini	NULL
M	NULL
,	NULL
Monne	NULL
M	NULL
,	NULL
Mazzoni	NULL
M	NULL
,	NULL
Capitani	NULL
S	NULL
:	NULL
The	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type-1	NULL
(	NULL
HIV-1	NULL
)	NULL
Tat	NULL
protein	NULL
upregulates	NULL
Bel-2	NULL
gene	NULL
expression	NULL
in	NULL
Jurkat	NULL
T	NULL
cell	NULL
lines	NULL
and	NULL
primary	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
.	NULL

Blood	NULL
86:3823	NULL
,	NULL
1995	NULL
30	NULL
.	NULL

Ensoli	NULL
B	NULL
,	NULL
Buonaguro	NULL
L	NULL
,	NULL
Barillari	NULL
G	NULL
,	NULL
Fiorelli	NULL
V	NULL
,	NULL
Gendelman	NULL
R	NULL
,	NULL
Morgan	NULL
RA	NULL
,	NULL
Wingfield	NULL
P	NULL
,	NULL
Gallo	NULL
RC	NULL
:	NULL
Release	NULL
,	NULL
uptake	NULL
,	NULL
and	NULL
effects	NULL
of	NULL
extracellular	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
Tat	NULL
protein	NULL
on	NULL
cell	NULL
growth	NULL
and	NULL
viral	NULL
transactivation	NULL
.	NULL

J	NULL
Virol	NULL
67:277	NULL
,	NULL
1993	NULL
31	NULL
.	NULL

Frankel	NULL
AD	NULL
,	NULL
Pabo	NULL
CO	NULL
:	NULL
Cellular	NULL
uptake	NULL
of	NULL
the	NULL
Tat	NULL
protein	NULL
from	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
.	NULL

Cell	NULL
55:1189	NULL
,	NULL
1988	NULL
32	NULL
.	NULL

Mann	NULL
DA	NULL
,	NULL
Frankel	NULL
AD	NULL
:	NULL
Endocytosis	NULL
and	NULL
targeting	NULL
of	NULL
exogenous	NULL
HIV-1	NULL
Tat	NULL
protein	NULL
.	NULL

EMBO	NULL
J	NULL
10:1733	NULL
,	NULL
1991	NULL
33	NULL
.	NULL

Fawell	NULL
S	NULL
,	NULL
Seery	NULL
J	NULL
,	NULL
Daikh	NULL
Y	NULL
,	NULL
Moore	NULL
C	NULL
,	NULL
Chen	NULL
LL	NULL
,	NULL
Pepinsky	NULL
B	NULL
,	NULL
Barsoum	NULL
J	NULL
:	NULL
Tat-mediated	NULL
delivery	NULL
of	NULL
heterologous	NULL
proteins	NULL
into	NULL
cells	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
91:664	NULL
,	NULL
1994	NULL
34	NULL
.	NULL

Helland	NULL
DE	NULL
,	NULL
Welles	NULL
JL	NULL
,	NULL
Caputo	NULL
A	NULL
,	NULL
Haseltine	NULL
WA	NULL
:	NULL
Transcellular	NULL
transactivation	NULL
by	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
fat	NULL
protein	NULL
.	NULL

J	NULL
Virol	NULL
65:4547	NULL
,	NULL
1991	NULL
35	NULL
.	NULL

Marcuzzi	NULL
A	NULL
,	NULL
Weinberger	NULL
J	NULL
,	NULL
Weinberger	NULL
OK	NULL
:	NULL
Transcellular	NULL
activation	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
long	NULL
terminal	NULL
repeat	NULL
in	NULL
cocultured	NULL
lymphocytes	NULL
.	NULL

J	NULL
Virol	NULL
66:4228	NULL
,	NULL
1992	NULL
36	NULL
.	NULL

Thomas	NULL
CA	NULL
,	NULL
Dobkin	NULL
J	NULL
,	NULL
Weinberger	NULL
OK	NULL
:	NULL
Tat-mediated	NULL
transcellular	NULL
activation	NULL
of	NULL
HIV-1	NULL
long	NULL
terminal	NULL
repeat	NULL
directed	NULL
gene	NULL
expression	NULL
by	NULL
HIV-l-infected	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
.	NULL

J	NULL
Immunol	NULL
153:3831	NULL
,	NULL
1994	NULL
37	NULL
.	NULL

Zauli	NULL
G	NULL
,	NULL
La	NULL
Placa	NULL
M	NULL
,	NULL
Vignoli	NULL
M	NULL
,	NULL
Re	NULL
MC	NULL
,	NULL
Gibellini	NULL
D	NULL
,	NULL
Furlini	NULL
G	NULL
,	NULL
Milani	NULL
D	NULL
,	NULL
Marchisio	NULL
M	NULL
,	NULL
Mazzoni	NULL
M	NULL
,	NULL
Capitani	NULL
S	NULL
:	NULL
An	NULL
autocrine	NULL
1663	NULL
loop	NULL
of	NULL
HIV	NULL
type	NULL
1	NULL
Tat	NULL
protein	NULL
responsible	NULL
for	NULL
the	NULL
improved	NULL
survival/	NULL
proliferation	NULL
capacity	NULL
of	NULL
permanently	NULL
tat-transfected	NULL
cells	NULL
and	NULL
required	NULL
for	NULL
optimal	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
long	NULL
terminal	NULL
repeat	NULL
transactivating	NULL
activity	NULL
.	NULL

J	NULL
AIDS	NULL
10:306	NULL
,	NULL
1995	NULL
38	NULL
.	NULL

Steinaa	NULL
L	NULL
,	NULL
Serensen	NULL
AM	NULL
,	NULL
Nielsen	NULL
JO	NULL
,	NULL
Hansen	NULL
JES	NULL
:	NULL
Antibody	NULL
to	NULL
HIV-1	NULL
Tat	NULL
protein	NULL
inhibits	NULL
the	NULL
replication	NULL
of	NULL
virus	NULL
in	NULL
culture	NULL
.	NULL

Arch	NULL
Virol	NULL
139:263	NULL
,	NULL
1994	NULL
39	NULL
.	NULL

Re	NULL
MC	NULL
,	NULL
Furlini	NULL
G	NULL
,	NULL
Vignoli	NULL
M	NULL
,	NULL
Ramazzotti	NULL
E	NULL
,	NULL
Roderigo	NULL
G	NULL
,	NULL
De	NULL
Rosa	NULL
V	NULL
,	NULL
Zauli	NULL
G	NULL
,	NULL
Lolli	NULL
S	NULL
,	NULL
Capitani	NULL
S	NULL
,	NULL
La	NULL
Placa	NULL
M	NULL
:	NULL
Effect	NULL
of	NULL
antibody	NULL
to	NULL
HIV-1	NULL
Tat	NULL
protein	NULL
on	NULL
viral	NULL
replication	NULL
in	NULL
vitro	NULL
and	NULL
progression	NULL
of	NULL
HIV-1	NULL
disease	NULL
in	NULL
vivo	NULL
.	NULL

J	NULL
AIDS	NULL
10:408	NULL
,	NULL
1995	NULL
40	NULL
.	NULL

Fauci	NULL
AS	NULL
:	NULL
Multifactorial	NULL
nature	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
disease	NULL
:	NULL
Implications	NULL
for	NULL
therapy	NULL
.	NULL

Science	NULL
262:1011	NULL
,	NULL
1993	NULL
41	NULL
.	NULL

Deschamps	NULL
J	NULL
,	NULL
Meijlink	NULL
F	NULL
,	NULL
Verma	NULL
IM	NULL
:	NULL
Identification	NULL
of	NULL
a	NULL
transcriptional	NULL
enhancer	NULL
element	NULL
uptream	NULL
from	NULL
the	NULL
proto-oncogene	NULL
fos	NULL
.	NULL

Science	NULL
230:1174	NULL
,	NULL
1985	NULL
42	NULL
.	NULL

Van	NULL
Straaten	NULL
F	NULL
,	NULL
Muller	NULL
R	NULL
,	NULL
Curran	NULL
T	NULL
,	NULL
van	NULL
Beveren	NULL
C	NULL
,	NULL
Verma	NULL
IM	NULL
:	NULL
Complete	NULL
nucleotide	NULL
sequence	NULL
of	NULL
human	NULL
c-onc	NULL
gene	NULL
:	NULL
Deduced	NULL
aminoacid	NULL
sequence	NULL
of	NULL
the	NULL
human	NULL
c-fos	NULL
protein	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
80:3183	NULL
,	NULL
1983	NULL
43	NULL
.	NULL

Fujii	NULL
M	NULL
,	NULL
Sassone-Corsi	NULL
P	NULL
,	NULL
Verma	NULL
IM	NULL
:	NULL
c-fos	NULL
promoter	NULL
transactivation	NULL
by	NULL
the	NULL
tax1	NULL
protein	NULL
of	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
1	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
85:8526	NULL
,	NULL
1988	NULL
44	NULL
.	NULL

Gibellini	NULL
D	NULL
,	NULL
Caputo	NULL
A	NULL
,	NULL
Celeghini	NULL
C	NULL
,	NULL
Bassini	NULL
A	NULL
,	NULL
La	NULL
Placa	NULL
M	NULL
,	NULL
Capitani	NULL
S	NULL
,	NULL
Zauli	NULL
G	NULL
:	NULL
Tat-expressing	NULL
Jurkat	NULL
cells	NULL
show	NULL
an	NULL
increased	NULL
resistance	NULL
to	NULL
different	NULL
apoptotic	NULL
stimuli	NULL
,	NULL
including	NULL
acute	NULL
human	NULL
immunodeficiency	NULL
virus-type	NULL
1	NULL
(	NULL
HIV-1	NULL
)	NULL
infection	NULL
.	NULL

Br	NULL
J	NULL
Haematol	NULL
89:24	NULL
,	NULL
1995	NULL
45	NULL
.	NULL

Sassone-Corsi	NULL
P	NULL
,	NULL
Lamph	NULL
WW	NULL
,	NULL
Verma	NULL
IM	NULL
:	NULL
Regulation	NULL
of	NULL
proto-oncogene	NULL
fos	NULL
:	NULL
A	NULL
paradigm	NULL
for	NULL
early	NULL
response	NULL
genes	NULL
.	NULL

Cold	NULL
Spring	NULL
Harbor	NULL
Symp	NULL
Quant	NULL
Biol	NULL
53:749	NULL
,	NULL
1988	NULL
46	NULL
.	NULL

Kastan	NULL
MB	NULL
,	NULL
Stone	NULL
KD	NULL
,	NULL
Civin	NULL
CI	NULL
:	NULL
Nuclear	NULL
oncoprotein	NULL
expression	NULL
as	NULL
a	NULL
function	NULL
of	NULL
lineage	NULL
,	NULL
differentiation	NULL
stage	NULL
,	NULL
and	NULL
proliferative	NULL
status	NULL
of	NULL
normal	NULL
human	NULL
hematopoietic	NULL
cells	NULL
.	NULL

Blood	NULL
74:1517	NULL
,	NULL
1989	NULL
47	NULL
.	NULL

Kerr	NULL
LD	NULL
,	NULL
Holt	NULL
JT	NULL
,	NULL
Matrisian	NULL
LM	NULL
:	NULL
Growth	NULL
factors	NULL
regulate	NULL
transin	NULL
gene	NULL
expression	NULL
by	NULL
c-fos-dependent	NULL
and	NULL
c-fos-independent	NULL
pathways	NULL
.	NULL

Science	NULL
242:1424	NULL
,	NULL
1988	NULL
48	NULL
.	NULL

Tremble	NULL
P	NULL
,	NULL
Damsky	NULL
CH	NULL
,	NULL
Werb	NULL
Z	NULL
:	NULL
Components	NULL
of	NULL
the	NULL
nuclear	NULL
signaling	NULL
cascade	NULL
that	NULL
regulate	NULL
collagenase	NULL
gene	NULL
expression	NULL
in	NULL
response	NULL
to	NULL
integrin-derived	NULL
signals	NULL
.	NULL

J	NULL
Cell	NULL
Biol	NULL
129:1707	NULL
,	NULL
1995	NULL
49	NULL
.	NULL

Angel	NULL
P	NULL
,	NULL
Imagawa	NULL
M	NULL
,	NULL
Chiu	NULL
R	NULL
,	NULL
Stein	NULL
B	NULL
,	NULL
Imbra	NULL
R	NULL
,	NULL
Rahmsdorf	NULL
J	NULL
,	NULL
Jonat	NULL
C	NULL
,	NULL
Herrlich	NULL
P	NULL
,	NULL
Karin	NULL
M	NULL
:	NULL
Phorbol	NULL
ester-inducible	NULL
genes	NULL
contain	NULL
a	NULL
common	NULL
cis-element	NULL
recognized	NULL
by	NULL
a	NULL
TPA-modulated	NULL
trans-acting	NULL
factor	NULL
.	NULL

Cell	NULL
49:729	NULL
,	NULL
1987	NULL
50	NULL
.	NULL

Franza	NULL
BR	NULL
,	NULL
Rauscher	NULL
FJ	NULL
,	NULL
Josephs	NULL
SF	NULL
,	NULL
Curran	NULL
T	NULL
:	NULL
The	NULL
fos	NULL
complex	NULL
and	NULL
fos	NULL
related	NULL
antigens	NULL
recognize	NULL
sequence	NULL
elements	NULL
that	NULL
contain	NULL
AP1	NULL
binding	NULL
sites	NULL
.	NULL

Science	NULL
239:1150	NULL
,	NULL
1989	NULL
51	NULL
.	NULL

Smeal	NULL
T	NULL
,	NULL
Angel	NULL
P	NULL
,	NULL
Meek	NULL
J	NULL
,	NULL
Karin	NULL
M	NULL
:	NULL
Different	NULL
requirements	NULL
for	NULL
the	NULL
formatin	NULL
of	NULL
Jun	NULL
:	NULL
Jun	NULL
and	NULL
Jun	NULL
:	NULL
Fos	NULL
complexes	NULL
.	NULL

Genes	NULL
Dev	NULL
3:2091	NULL
,	NULL
1989	NULL
52	NULL
.	NULL

Stein	NULL
B	NULL
,	NULL
Baldwin	NULL
AS	NULL
,	NULL
Ballard	NULL
DW	NULL
,	NULL
Greene	NULL
WC	NULL
,	NULL
Angel	NULL
P	NULL
,	NULL
Herrlich	NULL
P	NULL
:	NULL
Cross-coupling	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
/	NULL
#	NULL
p65	NULL
and	NULL
Fos/Jun	NULL
transcription	NULL
factors	NULL
produces	NULL
potential	NULL
biological	NULL
function	NULL
.	NULL

EMBO	NULL
J	NULL
12:3879	NULL
,	NULL
1993	NULL
53	NULL
.	NULL

Hai	NULL
T	NULL
,	NULL
Curran	NULL
T	NULL
:	NULL
Cross-family	NULL
dimerization	NULL
of	NULL
transcription	NULL
factors	NULL
Fos/jun	NULL
and	NULL
ATF/CREB	NULL
alters	NULL
DNA	NULL
binding	NULL
specificity	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
88:3720	NULL
,	NULL
1991	NULL
54	NULL
.	NULL

Buonaguro	NULL
L	NULL
,	NULL
Buonaguro	NULL
FM	NULL
,	NULL
Giraldo	NULL
G	NULL
,	NULL
Ensoli	NULL
B	NULL
:	NULL
The	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
Tat	NULL
protein	NULL
transactivates	NULL
tumor	NULL
necrosis	NULL
factor	NULL
beta	NULL
gene	NULL
expression	NULL
through	NULL
a	NULL
TAR-like	NULL
structure	NULL
.	NULL

J	NULL
Virol	NULL
68:2677	NULL
,	NULL
1994	NULL
55	NULL
.	NULL

Chowdhury	NULL
M	NULL
,	NULL
Taylor	NULL
JP	NULL
,	NULL
Chang	NULL
CF	NULL
,	NULL
Rappaport	NULL
J	NULL
,	NULL
Khalili	NULL
K	NULL
:	NULL
Evidence	NULL
that	NULL
a	NULL
sequence	NULL
similar	NULL
to	NULL
TAR	NULL
is	NULL
important	NULL
for	NULL
induction	NULL
of	NULL
the	NULL
JC	NULL
virus	NULL
late	NULL
promoter	NULL
by	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
Tat	NULL
.	NULL

J	NULL
Virol	NULL
66:7355	NULL
,	NULL
1992	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

1664	NULL
56	NULL
.	NULL

Brake	NULL
DA	NULL
,	NULL
Debouck	NULL
C	NULL
,	NULL
Biesecher	NULL
G	NULL
:	NULL
Identification	NULL
of	NULL
an	NULL
Arg-Gly-Asp	NULL
(	NULL
RGD	NULL
)	NULL
cell	NULL
adhesion	NULL
site	NULL
in	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
transactivation	NULL
protein	NULL
,	NULL
Tat	NULL
.	NULL

J	NULL
Cell	NULL
Biol	NULL
111:1275,1990	NULL
57	NULL
.	NULL

Vogel	NULL
BE	NULL
,	NULL
Lee	NULL
SJ	NULL
,	NULL
Hildebrand	NULL
A	NULL
,	NULL
Craig	NULL
W	NULL
,	NULL
Pierschbacher	NULL
MD	NULL
,	NULL
Wong-Staal	NULL
F	NULL
,	NULL
Ruoslahti	NULL
E	NULL
:	NULL
A	NULL
novel	NULL
integrin	NULL
specificify	NULL
exemplified	NULL
by	NULL
binding	NULL
of	NULL
the	NULL
av/5	NULL
integrin	NULL
to	NULL
the	NULL
basic	NULL
domain	NULL
of	NULL
the	NULL
HIV	NULL
tat	NULL
protein	NULL
and	NULL
vitronectin	NULL
.	NULL

J	NULL
Cell	NULL
Biol	NULL
121:461	NULL
,	NULL
1993	NULL
58	NULL
.	NULL

Weeks	NULL
BS	NULL
,	NULL
Desai	NULL
K	NULL
,	NULL
Loewenstein	NULL
PM	NULL
,	NULL
Klotman	NULL
ME	NULL
,	NULL
Klotman	NULL
P	NULL
,	NULL
Green	NULL
M	NULL
,	NULL
Kleinman	NULL
HK	NULL
:	NULL
Identification	NULL
of	NULL
a	NULL
novel	NULL
cell	NULL
attachment	NULL
domain	NULL
in	NULL
the	NULL
HIV-1	NULL
Tat	NULL
protein	NULL
and	NULL
its	NULL
90-kDa	NULL
cell	NULL
surface	NULL
binding	NULL
protein	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
268:5279	NULL
,	NULL
1993	NULL
59	NULL
.	NULL

Barillari	NULL
G	NULL
,	NULL
Gendelman	NULL
R	NULL
,	NULL
Gallo	NULL
RC	NULL
,	NULL
Ensoli	NULL
B	NULL
:	NULL
The	NULL
tat	NULL
protein	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
,	NULL
a	NULL
growth	NULL
factor	NULL
for	NULL
AIDS	NULL
Kaposi	NULL
sarcoma	NULL
and	NULL
cytokine-activated	NULL
vascular	NULL
cells	NULL
,	NULL
induces	NULL
adhesion	NULL
of	NULL
the	NULL
same	NULL
types	NULL
by	NULL
using	NULL
integrin	NULL
receptors	NULL
GIBELLINI	NULL
ET	NULL
AL	NULL
recognizing	NULL
RGD	NULL
amino	NULL
acid	NULL
sequence	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
90:7941	NULL
,	NULL
1993	NULL
60	NULL
.	NULL

Yamada	NULL
A	NULL
,	NULL
Nikaido	NULL
T	NULL
,	NULL
Nojima	NULL
Y	NULL
,	NULL
Schlossman	NULL
SF	NULL
,	NULL
Marimoto	NULL
C	NULL
:	NULL
Activation	NULL
of	NULL
Human	NULL
CD4	NULL
T	NULL
lymphocytes	NULL
.	NULL

Interaction	NULL
of	NULL
fibro-nectin	NULL
with	NULL
VLA-5	NULL
receptor	NULL
on	NULL
CD4	NULL
cells	NULL
induces	NULL
the	NULL
AP-1	NULL
transcription	NULL
factor	NULL
.	NULL

J	NULL
Immunol	NULL
146:53	NULL
,	NULL
1991	NULL
61	NULL
.	NULL

Tay	NULL
DLM	NULL
,	NULL
Hoffbrand	NULL
AV	NULL
,	NULL
Wickremasinghe	NULL
RG	NULL
:	NULL
Expression	NULL
of	NULL
c-fos	NULL
and	NULL
c-jun	NULL
proteins	NULL
and	NULL
AP-1	NULL
binding	NULL
activity	NULL
during	NULL
cell	NULL
cycle	NULL
progression	NULL
of	NULL
HL60	NULL
cells	NULL
and	NULL
phytohemagglutinin-stimulated	NULL
lymphocytes	NULL
.	NULL

Exp	NULL
Hematol	NULL
24:277	NULL
,	NULL
1996	NULL
62	NULL
.	NULL

Nabel	NULL
G	NULL
,	NULL
Baltimore	NULL
D	NULL
:	NULL
An	NULL
inducible	NULL
transcription	NULL
factor	NULL
activates	NULL
expression	NULL
of	NULL
human	NULL
immmunodeficiency	NULL
virus	NULL
in	NULL
T-cell	NULL
.	NULL

Nature	NULL
326:711	NULL
,	NULL
1987	NULL
63	NULL
.	NULL

Roebuck	NULL
KA	NULL
,	NULL
Brenner	NULL
DA	NULL
,	NULL
Kagnoff	NULL
MF	NULL
:	NULL
Identification	NULL
of	NULL
c-fos-responsive	NULL
elements	NULL
downstream	NULL
of	NULL
TAR	NULL
in	NULL
the	NULL
long	NULL
terminal	NULL
repeat	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type-1	NULL
.	NULL

J	NULL
Clin	NULL
Invest	NULL
92:1336	NULL
,	NULL
1993	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

®	NULL
blO	NULL
0d	NULL
1997	NULL
89	NULL
:	NULL
1654-1664	NULL
Upregulation	NULL
of	NULL
c-Fos	NULL
in	NULL
Activated	NULL
T	NULL
Lymphoid	NULL
and	NULL
Monocytic	NULL
Cells	NULL
by	NULL
Human	NULL
Immunodeficiency	NULL
Virus-1	NULL
Tat	NULL
Protein	NULL
4	NULL
_	NULL
5	NULL
,	NULL
'	NULL
_	NULL
>	NULL
,	NULL
#	NULL
04	NULL
;	NULL
©1004	NULL
@	NULL
207	NULL
Davide	NULL
Gibellini	NULL
,	NULL
Antonella	NULL
Caputo	NULL
,	NULL
Silvano	NULL
Capitani	NULL
,	NULL
Michele	NULL
La	NULL
Placa	NULL
and	NULL
Giorgio	NULL
Zauli	NULL
Updated	NULL
information	NULL
and	NULL
services	NULL
can	NULL
be	NULL
found	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/content/89/5/1654.full.html	NULL
Articles	NULL
on	NULL
similar	NULL
topics	NULL
can	NULL
be	NULL
found	NULL
in	NULL
the	NULL
following	NULL
Blood	NULL
collections	NULL
Immunobiology	NULL
and	NULL
Immunotherapy	NULL
(	NULL
5678	NULL
articles	NULL
)	NULL
Information	NULL
about	NULL
reproducing	NULL
this	NULL
article	NULL
in	NULL
parts	NULL
or	NULL
in	NULL
its	NULL
entirety	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
requests	NULL
Information	NULL
about	NULL
ordering	NULL
reprints	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/site/misc/rights.xhtml	NULL
#	NULL
reprints	NULL
Information	NULL
about	NULL
subscriptions	NULL
and	NULL
ASH	NULL
membership	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/site/subscriptions/index.xhtml	NULL
Blood	NULL
(	NULL
print	NULL
ISSN	NULL
0006-4971	NULL
,	NULL
online	NULL
ISSN	NULL
1528-0020	NULL
)	NULL
,	NULL
is	NULL
published	NULL
weekly	NULL
by	NULL
the	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
,	NULL
2021	NULL
L	NULL
St	NULL
,	NULL
NW	NULL
,	NULL
Suite	NULL
900	NULL
,	NULL
Washington	NULL
DC	NULL
20036	NULL
.	NULL

Copyright	NULL
2011	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
;	NULL
all	NULL
rights	NULL
reserved	NULL
.	NULL

